0001178913-19-002055.txt : 20190806 0001178913-19-002055.hdr.sgml : 20190806 20190806071123 ACCESSION NUMBER: 0001178913-19-002055 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 34 CONFORMED PERIOD OF REPORT: 20190630 FILED AS OF DATE: 20190806 DATE AS OF CHANGE: 20190806 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BioLineRx Ltd. CENTRAL INDEX KEY: 0001498403 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: L3 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35223 FILM NUMBER: 191000408 BUSINESS ADDRESS: STREET 1: 2 HAMA-AYAN STREET STREET 2: MODI-IN TECHNOLOGY PARK CITY: MODI-IN STATE: L3 ZIP: 7177871 BUSINESS PHONE: 972-2-548-9100 MAIL ADDRESS: STREET 1: 2 HAMA-AYAN STREET STREET 2: MODI-IN TECHNOLOGY PARK CITY: MODI-IN STATE: L3 ZIP: 7177871 FORMER COMPANY: FORMER CONFORMED NAME: BioLineRX, Ltd. DATE OF NAME CHANGE: 20100805 6-K 1 zk1923342.htm 6-K

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 OF

THE SECURITIES EXCHANGE ACT OF 1934

For the month of August 2019

_______________________

BioLineRx Ltd.

(Translation of registrant’s name into English)

_______________________

2 HaMa’ayan Street
Modi’in 7177871, Israel

(Address of Principal Executive Offices)

_______________________

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ☑ Form 40-F ☐

Indicate by check mark whether the registrant by furnishing the information contained in this form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934:

Yes ☐ No ☑

On August 6, 2019, the registrant will issue a press release announcing its financial results for the three and six months ended June 30, 2019. The registrant is also publishing its unaudited interim consolidated financial statements, as well as its operating and financial review, as of June 30, 2019 and for the three and six months then ended. Attached hereto are the following exhibits:

Exhibit 1: Registrant’s press release dated August 6, 2019;

Exhibit 2: Registrant’s condensed consolidated interim financial statements as of June 30, 2019, and for the three and six months and then ended; and

Exhibit 3 - Registrant’s operating and financial review as of June 30, 2019, and for the three and six months then ended.

This Form 6-K, including all exhibits hereto, is hereby incorporated by reference into all effective registration statements filed by the registrant under the Securities Act of 1933.

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	BioLineRx Ltd.
	By:	/s/ Philip A. Serlin
		Philip A. Serlin
		Chief Executive Officer

Dated: August 6, 2019

EX-99 2 exhibit_1.htm REGISTRANT'S PRESS RELEASE DATED AUGUST 6, 2019

Exhibit 1

For Immediate Release

BioLineRx Reports Second Quarter 2019 Financial Results

and Provides Corporate Update

On track for Phase 2 data read-out in pancreatic cancer by year-end 2019

Management to hold conference call today, August 6, at 10:00 am EDT

TEL AVIV, Israel, August 6, 2019 -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology, today reports its financial results for the quarter ended June 30, 2019 and provides a corporate update.

Highlights and achievements during the second quarter 2019 and subsequent period:

•

Continued to advance multiple clinical trials of its lead therapeutic candidates, BL-8040 and AGI-134, and anticipates top-line data from the triple combination arm of the COMBAT/KEYNOTE-202 pancreatic cancer trial by year-end.

•

Received approval from the FDA for an Investigational New Drug (IND) application for AGI-134, which will enable expansion of the ongoing Phase 1/2a study, currently being carried out in the UK and Israel, to the US by the first half of 2020.

“BL-8040, our lead drug candidate, is rapidly advancing in multiple promising programs. The triple combination arm of our ongoing COMBAT/KEYNOTE-202 Phase 2 study of BL-8040, KEYTRUDA^® and chemotherapy in metastatic pancreatic cancer is progressing as planned, and top-line results are expected by year end. AML consolidation also remains an important indication in our BL-8040 development plan, and we, with our partners, continue to progress our BLAST Phase 2b study towards a robust interim analysis. In addition, the GENESIS Phase 3 study in stem cell mobilization, our most advanced indication and most direct path to registration, is progressing as planned with top-line results expected in the second half of next year,” stated Philip Serlin, Chief Executive Officer of BioLineRx.

“Regarding our second clinical candidate, the universal anti-cancer vaccine AGI-134, we continue to advance our phase 1/2a clinical trial toward initial safety data later this year, and with the acceptance of our IND, we look forward to the next part of the study, which will assess potential efficacy. Taken together, we believe our broad development pipeline provides multiple opportunities for long-term value creation and we are diligently working toward that goal,” Mr. Serlin concluded.

Upcoming Milestones

Second half of 2019

•

Top-line results from COMBAT/KEYNOTE-202 Phase 2 pancreatic cancer trial

•

Initial safety results from part 1 of Phase 1/2a trial of AGI-134

•

Potential interim results from Phase 2b AML consolidation study

•

Initiation of monotherapy basket arm of Part 2 of Phase 1/2a trial of AGI-134

2020

•

Progression-free survival (PFS) and overall survival (OS) data from COMBAT/KEYNOTE-202 trial in mid-2020

•

Top-line results from Phase 3 GENESIS registration trial in stem-cell mobilization in second half of 2020

Financial Results for the Second Quarter Ended June 30, 2019

Research and development expenses for the three months ended June 30, 2019 were $5.3 million, an increase of $0.8 million, or 18%, compared to $4.5 million for the three months ended June 30, 2018. The increase resulted primarily from higher expenses associated with the BL-8040 GENESIS and COMBAT clinical trials. Research and development expenses for the six months ended June 30, 2019 were $9.7 million, an increase of $0.1 million, or 2%, compared to $9.6 million for the six months ended June 30, 2018. The small increase resulted primarily from higher expenses associated with the BL-8040 GENESIS and COMBAT clinical trials, offset by a decrease in expenses related to BL-1230, a project which was terminated, as well as a decrease in payroll and related expenses.

Sales and marketing expenses for the three months ended June 30, 2019 were $0.2 million, a decrease of $0.1 million, or 37%, compared to $0.3 million for the three months ended June 30, 2018. The decrease resulted primarily from a decrease in payroll and related expenses. Sales and marketing expenses for the six months ended June 30, 2019 were $0.5 million, a decrease of $0.4 million, or 43%, compared to $0.9 million for the six months ended June 30, 2018. The decrease resulted primarily from a decrease in payroll and related expenses, including a one-time compensation payment in the 2018 period.

General and administrative expenses for the three months ended June 30, 2019 were $0.9 million, similar to the comparable period in 2018. General and administrative expenses for the six months ended June 30, 2019 were $1.9 million, similar to the comparable period in 2018.

The Company’s operating loss for the three months ended June 30, 2019 was $6.5 million, compared to $5.7 million for the three months ended June 30, 2018. The Company’s operating loss for the six months ended June 30, 2019 was $12.1 million, compared to $12.4 million for the comparable period in 2018.

Non-operating income for the three and six months ended June 30, 2019 primarily relates to fair-value adjustments of warrant liabilities on the Company’s balance sheet, offset by warrant offering expenses. Non-operating income for the six months ended June 30, 2018 primarily relates to fair-value adjustments of warrant liabilities on the Company’s balance sheet, as well as a capital gain from realization of the investment in iPharma.

Net financial expenses amounted to $0.3 million for the three months ended June 30, 2019 compared to net financial income of $0.3 million for the three months ended June 30, 2018. Net financial expenses for the 2019 period primarily relate to interest paid on loans, offset by investment income earned on bank deposits. Net financial income for the 2018 period primarily relates to investment income earned on bank deposits, offset by losses recorded on foreign currency hedging transactions. Net financial expenses amounted to $0.5 million for the six months ended June 30, 2019 compared to net financial income of $0.3 million for the six months ended June 30, 2018. Net financial expenses for the 2019 period primarily relate to interest paid on loans, offset by investment income earned on bank deposits. Net financial income for the 2018 period primarily relates to investment income earned on bank deposits, offset by losses recorded on foreign currency hedging transactions.

The Company’s net loss for the three months ended June 30, 2019 amounted to $5.5 million, compared with a net loss of $4.8 million for the comparable period in 2018. The Company’s net loss for the six months ended June 30, 2019 amounted to $11.6 million, compared with a net loss of $11.0 million for the comparable period in 2018.

The Company held $35.2 million in cash, cash equivalents and short-term bank deposits as of June 30, 2019.

Net cash used in operating activities was $11.1 million for the six months ended June 30, 2019, compared with net cash used in operating activities of $13.0 million for the six months ended June 30, 2018. The $1.9 million decrease in net cash used in operating activities during the six-month period in 2019, compared to the six-month period in 2018, was primarily the result of changes in operating asset and liability items in the two periods., i.e., a decrease in prepaid expenses and other receivables in 2019 versus an increase in 2018, as well as a higher decrease in accounts payable and accruals in 2018.

Net cash used in investing activities was $3.1 million for the six months ended June 30, 2019, compared to net cash provided by investing activities of $10.8 million for the six months ended June 30, 2018. The changes in cash flows from investing activities relate primarily to investments in, and maturities of, short-term bank deposits and the realization of the investment in iPharma in 2018.

Net cash provided by financing activities was $15.7 million for the six months ended June 30, 2019, compared to net cash provided by financing activities of $2.8 million for the six months ended June 30, 2018. The increase in cash flows from financing activities reflects the underwritten public offering completed in February 2019.

Conference Call and Webcast Information

BioLineRx will hold a conference call today, August 6, 2019 at 10:00 a.m. EDT. To access the conference call, please dial +1-888-281-1167 from the U.S. or +972-3-918-0644 internationally. The call will also be available via webcast and can be accessed through the Investor Relations page of BioLineRx’s website. Please allow extra time prior to the call to visit the site and download any necessary software to listen to the live broadcast.

A replay of the conference call will be available approximately two hours after completion of the live conference call on the Investor Relations page of BioLineRx’s website. A dial-in replay of the call will be available until August 8, 2019; please dial +1-888-295-2634 from the U.S. or +972-3-925-5904 internationally.

(Tables follow)

About BioLineRx

BioLineRx is a clinical-stage biopharmaceutical company focused on oncology. The Company in-licenses novel compounds, develops them through pre-clinical and/or clinical stages, and then partners with pharmaceutical companies for advanced clinical development and/or commercialization.

BioLineRx’s leading therapeutic candidates are: BL-8040, a cancer therapy platform, which has successfully completed a Phase 2a study for relapsed/refractory AML, is in the midst of a Phase 2b study as an AML consolidation treatment and a Phase 3 study in stem cell mobilization for autologous transplantation; and AGI-134, an immunotherapy treatment in development for multiple solid tumors, which is being investigated in a Phase 1/2a study. In addition, BioLineRx has a strategic collaboration with Novartis for the co-development of selected Israeli-sourced novel drug candidates; a collaboration agreement with MSD, on the basis of which the Company is conducting a Phase 2a study in pancreatic cancer using the combination of BL-8040 and KEYTRUDA® (pembrolizumab), and a collaboration agreement with Genentech, a member of the Roche Group, to investigate the combination of BL-8040 and Genentech’s atezolizumab in two Phase 1b/2 studies for solid tumor indications.

For additional information on BioLineRx, please visit the Company’s website at www.biolinerx.com, where you can review the Company’s SEC filings, press releases, announcements and events. BioLineRx industry updates are also regularly updated on Facebook, Twitter, and LinkedIn.

Various statements in this release concerning BioLineRx’s future expectations constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include words such as “may,” “expects,” “anticipates,” “believes,” and “intends,” and describe opinions about future events. These forward-looking statements involve known and unknown risks and uncertainties that may cause the actual results, performance or achievements of BioLineRx to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Some of these risks are: changes in relationships with collaborators; the impact of competitive products and technological changes; risks relating to the development of new products; and the ability to implement technological improvements. These and other factors are more fully discussed in the “Risk Factors” section of BioLineRx’s most recent annual report on Form 20-F filed with the Securities and Exchange Commission on March 28, 2019. In addition, any forward-looking statements represent BioLineRx’s views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. BioLineRx does not assume any obligation to update any forward-looking statements unless required by law.

Contact:

Tim McCarthy

LifeSci Advisors, LLC

+1-212-915-2564

tim@lifesciadvisors.com

Tsipi Haitovsky

Public Relations

+972-52-598-9892

tsipihai5@gmail.com

BioLineRx Ltd.

CONDENSED CONSOLIDATED INTERIM STATEMENTS OF FINANCIAL POSITION

(UNAUDITED)

	December 31,			June 30,
	2018			2019
	in USD thousands
Assets
CURRENT ASSETS
Cash and cash equivalents		3,404			4,972
Short-term bank deposits		26,747			30,256
Prepaid expenses		488			451
Other receivables		1,339			528
Total current assets		31,978			36,207

NON-CURRENT ASSETS
Long-term prepaid expenses		56			60
Property and equipment, net		2,227			2,047
Right-of-use assets		-			1,716
Intangible assets, net		21,972			21,928
Total non-current assets		24,255			25,751
Total assets		56,233			61,958

Liabilities and equity
CURRENT LIABILITIES
Current maturities of long-term loans		895			2,395
Accounts payable and accruals:
Trade		4,493			4,565
Other		1,363			927
Lease liabilities		-			672
Total current liabilities		6,751			8,559
NON-CURRENT LIABILITIES
Warrants		323			3,938
Long-term loans, net of current maturities		7,838			6,583
Lease liabilities		-			1,096
Total non-current liabilities		8,161			11,617
COMMITMENTS AND CONTINGENT LIABILITIES
Total liabilities		14,912			20,176

EQUITY
Ordinary shares		3,110			4,001
Share premium		250,192			261,522
Capital reserve		11,955			11,835
Other comprehensive loss		(1,416	)		(1,416	)
Accumulated deficit		(222,520	)		(234,160	)
Total equity		41,321			41,782
Total liabilities and equity		56,233			61,958

BioLineRx Ltd.

CONDENSED CONSOLIDATED INTERIM STATEMENTS OF COMPREHENSIVE LOSS

(UNAUDITED)

	Three months ended June 30,						Six months ended June 30,
	2018			2019			2018			2019
	in USD thousands						in USD thousands
RESEARCH AND DEVELOPMENT EXPENSES		(4,484	)		(5,302	)		(9,554	)		(9,694	)
SALES AND MARKETING EXPENSES		(360	)		(226	)		(844	)		(482	)
GENERAL AND ADMINISTRATIVE EXPENSES		(883	)		(949	)		(1,958	)		(1,879	)
OPERATING LOSS		(5,727	)		(6,477	)		(12,356	)		(12,055	)
NON-OPERATING INCOME, NET		663			1,261			1,125			921
FINANCIAL INCOME		287			171			462			381
FINANCIAL EXPENSES		(11	)		(440	)		(217	)		(887	)

NET LOSS AND COMPREHENSIVE LOSS		(4,788	)		(5,485	)		(10,986	)		(11,640	)

	in USD						in USD
LOSS PER ORDINARY SHARE - BASIC AND DILUTED		(0.05	)		(0.04	)		(0.10	)		(0.08	)

WEIGHTED AVERAGE NUMBER OF SHARES USED IN CALCULATION OF LOSS PER ORDINARY SHARE		106,630,704			145,461,598			106,524,332			139,270,178

BioLineRx Ltd.

CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CHANGES IN EQUITY

(UNAUDITED)

	Ordinary		Share		Capital			Other Comprehensive			Accumulated
	shares		premium		reserve			loss			deficit			Total
	in USD thousands
BALANCE AT JANUARY 1, 2018		2,836		240,682		10,337			(1,416	)		(199,558	)		52,881
CHANGES FOR SIX MONTHS ENDED JUNE 30, 2018:
Issuance of share capital, net		83		2,764		-			-			-			2,847
Employee stock options exercised		1		38		(39	)		-			-			-
Employee stock options forfeited and expired		-		399		(399	)		-			-			-
Share-based compensation		-		-		1,444			-			-			1,444
Comprehensive loss for the period		-		-		-			-			(10,986	)		(10,986	)
BALANCE AT JUNE 30, 2018		2,920		243,883		11,343			(1,416	)		(210,544	)		46,186

	Ordinary		Share		Capital			Other Comprehensive			Accumulated
	shares		premium		reserve			loss			deficit			Total
	in USD thousands
BALANCE AT JANUARY 1, 2019		3,110		250,192		11,955			(1,416	)		(222,520	)		41,321
CHANGES FOR SIX MONTHS ENDED JUNE 30, 2019:
Issuance of share capital, net		890		10,437		-			-			-			11,327
Employee stock options exercised		1		27		(27	)		-			-			1
Employee stock options forfeited and expired		-		866		(866	)		-			-			-
Share-based compensation		-		-		773			-			-			773
Comprehensive loss for the period		-		-		-			-			(11,640	)		(11,640	)
BALANCE AT JUNE 30, 2019		4,001		261,522		11,835			(1,416	)		(234,160	)		41,782

BioLineRx Ltd.

CONDENSED CONSOLIDATED INTERIM CASH FLOW STATEMENTS

(UNAUDITED)

	Six months ended June 30,
	2018			2019
	in USD thousands

CASH FLOWS - OPERATING ACTIVITIES
Comprehensive loss for the period		(10,986	)		(11,640	)
Adjustments required to reflect net cash used in operating activities (see appendix below)		(2,054	)		573
Net cash used in operating activities		(13,040	)		(11,067	)

CASH FLOWS - INVESTING ACTIVITIES
Investments in short-term deposits		(15,000	)		(27,510	)
Maturities of short-term deposits		24,385			24,441
Proceeds from realization of long-term investment		1,500			-
Purchase of property and equipment		(76	)		(53	)
Purchase of intangible assets		(37	)		-
Net cash provided by (used in) investing activities		10,772			(3,122	)

CASH FLOWS - FINANCING ACTIVITIES
Issuances of share capital and warrants, net of issuance cost		2,847			15,879
Employee stock options exercised		-			1
Repayments of loans		(47	)		(47	)
Repayments of lease liabilities		-			(110	)
Net cash provided by financing activities		2,800			15,723

INCREASE IN CASH AND CASH EQUIVALENTS		532			1,534
CASH AND CASH EQUIVALENTS – BEGINNING OF PERIOD		5,110			3,404
EXCHANGE DIFFERENCES ON CASH AND CASH EQUIVALENTS		147			34
CASH AND CASH EQUIVALENTS - END OF PERIOD		5,789			4,972

BioLineRx Ltd.

APPENDIX TO CONDENSED CONSOLIDATED INTERIM CASH FLOW STATEMENTS

(UNAUDITED)

	Six months ended June 30,
	2018			2019
	in USD thousands

Adjustments required to reflect net cash used in operating activities:
Income and expenses not involving cash flows:
Depreciation and amortization		288			439
Long-term prepaid expenses		(2	)		(4	)
Exchange differences on cash and cash equivalents		(147	)		(34	)
Gain on adjustment of warrants to fair value		(625	)		(1,354	)
Gain on realization of long-term investment		(500	)		-
Share-based compensation		1,444			773
Warrant issuance costs		-			417
Interest and exchange rate differences on short-term deposits		(351	)		(440	)
Interest on loans		(1	)		292
		106			89

Changes in operating asset and liability items:
Decrease (increase) in prepaid expenses and other receivables		(776	)		848
Decrease in accounts payable and accruals		(1,384	)		(364	)
		(2,160	)		484
		(2,054	)		573

Supplemental information on interest received in cash		377			442

Supplemental information on interest paid in cash		167			477

Supplemental information on non-cash transaction -
Initial establishment of right-of-use assets against lease liabilities		-			1,878

EX-99 3 exhibit_2.htm CONSOLIDATED INTERIM FINANCIAL STATEMENTS AS OF JUNE 30, 2019.

Exhibit 2

BioLineRx Ltd.

CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

(UNAUDITED)

AS OF JUNE 30, 2019

BioLineRx Ltd.

CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

(UNAUDITED)

AS OF JUNE 30, 2019

TABLE OF CONTENTS

		Page
Condensed consolidated interim statements of financial position		F-1
Condensed consolidated interim statements of comprehensive loss		F-2
Condensed consolidated interim statements of changes in equity		F-3
Condensed consolidated interim cash flow statements		F-4 - F-5
Notes to the condensed consolidated interim financial statements		F-6 - F-9

BioLineRx Ltd.

CONDENSED CONSOLIDATED INTERIM STATEMENTS OF FINANCIAL POSITION

(UNAUDITED)

	December 31,			June 30,
	2018			2019
	in USD thousands
Assets
CURRENT ASSETS
Cash and cash equivalents		3,404			4,972
Short-term bank deposits		26,747			30,256
Prepaid expenses		488			451
Other receivables		1,339			528
Total current assets		31,978			36,207

NON-CURRENT ASSETS
Long-term prepaid expenses		56			60
Property and equipment, net		2,227			2,047
Right-of-use assets		-			1,716
Intangible assets, net		21,972			21,928
Total non-current assets		24,255			25,751
Total assets		56,233			61,958

Liabilities and equity
CURRENT LIABILITIES
Current maturities of long-term loans		895			2,395
Accounts payable and accruals:
Trade		4,493			4,565
Other		1,363			927
Lease liabilities		-			672
Total current liabilities		6,751			8,559
NON-CURRENT LIABILITIES
Warrants		323			3,938
Long-term loans, net of current maturities		7,838			6,583
Lease liabilities		-			1,096
Total non-current liabilities		8,161			11,617
COMMITMENTS AND CONTINGENT LIABILITIES
Total liabilities		14,912			20,176

EQUITY
Ordinary shares		3,110			4,001
Share premium		250,192			261,522
Capital reserve		11,955			11,835
Other comprehensive loss		(1,416	)		(1,416	)
Accumulated deficit		(222,520	)		(234,160	)
Total equity		41,321			41,782
Total liabilities and equity		56,233			61,958

The accompanying notes are an integral part of these condensed consolidated interim financial statements.

F - 1

BioLineRx Ltd.

CONDENSED CONSOLIDATED INTERIM STATEMENTS OF COMPREHENSIVE LOSS

(UNAUDITED)

	Three months ended June 30,						Six months ended June 30,
	2018			2019			2018			2019
	in USD thousands						in USD thousands
RESEARCH AND DEVELOPMENT EXPENSES		(4,484	)		(5,302	)		(9,554	)		(9,694	)
SALES AND MARKETING EXPENSES		(360	)		(226	)		(844	)		(482	)
GENERAL AND ADMINISTRATIVE EXPENSES		(883	)		(949	)		(1,958	)		(1,879	)
OPERATING LOSS		(5,727	)		(6,477	)		(12,356	)		(12,055	)
NON-OPERATING INCOME, NET		663			1,261			1,125			921
FINANCIAL INCOME		287			171			462			381
FINANCIAL EXPENSES		(11	)		(440	)		(217	)		(887	)

NET LOSS AND COMPREHENSIVE LOSS		(4,788	)		(5,485	)		(10,986	)		(11,640	)

	in USD					in USD
LOSS PER ORDINARY SHARE - BASIC AND DILUTED		(0.05	)	(0.04	)		(0.10	)	(0.08	)

WEIGHTED AVERAGE NUMBER OF SHARES USED IN CALCULATION OF LOSS PER ORDINARY SHARE		106,630,704		145,461,598			106,524,332		139,270,178

The accompanying notes are an integral part of these condensed consolidated interim financial statements.

F - 2

BioLineRx Ltd.

CONDENSED INTERIM STATEMENTS OF CHANGES IN EQUITY

(UNAUDITED)

	Ordinary		Share		Capital			Other Comprehensive			Accumulated
	shares		premium		reserve			loss			deficit			Total
	in USD thousands
BALANCE AT JANUARY 1, 2018		2,836		240,682		10,337			(1,416	)		(199,558	)		52,881
CHANGES FOR SIX MONTHS ENDED JUNE 30, 2018:
Issuance of share capital, net		83		2,764		-			-			-			2,847
Employee stock options exercised		1		38		(39	)		-			-			-
Employee stock options forfeited and expired		-		399		(399	)		-			-			-
Share-based compensation		-		-		1,444			-			-			1,444
Comprehensive loss for the period		-		-		-			-			(10,986	)		(10,986	)
BALANCE AT JUNE 30, 2018		2,920		243,883		11,343			(1,416	)		(210,544	)		46,186

	Ordinary		Share		Capital			Other Comprehensive			Accumulated
	shares		premium		reserve			loss			deficit			Total
	in USD thousands
BALANCE AT JANUARY 1, 2019		3,110		250,192		11,955			(1,416	)		(222,520	)		41,321
CHANGES FOR SIX MONTHS ENDED JUNE 30, 2019:
Issuance of share capital, net		890		10,437		-			-			-			11,327
Employee stock options exercised		1		27		(27	)		-			-			1
Employee stock options forfeited and expired		-		866		(866	)		-			-			-
Share-based compensation		-		-		773			-			-			773
Comprehensive loss for the period		-		-		-			-			(11,640	)		(11,640	)
BALANCE AT JUNE 30, 2019		4,001		261,522		11,835			(1,416	)		(234,160	)		41,782

The accompanying notes are an integral part of these condensed consolidated interim financial statements.

F - 3

BioLineRx Ltd.

CONDENSED CONSOLIDATED INTERIM CASH FLOW STATEMENTS

(UNAUDITED)

	Six months ended June 30,
	2018			2019
	in USD thousands

CASH FLOWS - OPERATING ACTIVITIES
Comprehensive loss for the period		(10,986	)		(11,640	)
Adjustments required to reflect net cash used in operating activities (see appendix below)		(2,054	)		573
Net cash used in operating activities		(13,040	)		(11,067	)

CASH FLOWS - INVESTING ACTIVITIES
Investments in short-term deposits		(15,000	)		(27,510	)
Maturities of short-term deposits		24,385			24,441
Proceeds from realization of long-term investment		1,500			-
Purchase of property and equipment		(76	)		(53	)
Purchase of intangible assets		(37	)		-
Net cash provided by (used in) investing activities		10,772			(3,122	)

CASH FLOWS - FINANCING ACTIVITIES
Issuances of share capital and warrants, net of issuance cost		2,847			15,879
Employee stock options exercised		-			1
Repayments of loans		(47	)		(47	)
Repayments of lease liabilities		-			(110	)
Net cash provided by financing activities		2,800			15,723

INCREASE IN CASH AND CASH EQUIVALENTS		532			1,534
CASH AND CASH EQUIVALENTS – BEGINNING OF PERIOD		5,110			3,404
EXCHANGE DIFFERENCES ON CASH AND CASH EQUIVALENTS		147			34
CASH AND CASH EQUIVALENTS - END OF PERIOD		5,789			4,972

The accompanying notes are an integral part of these condensed consolidated interim financial statements.

F - 4

BioLineRx Ltd.

APPENDIX TO CONDENSED CONSOLIDATED INTERIM CASH FLOW STATEMENTS

(UNAUDITED)

	Six months ended June 30,
	2018			2019
	in USD thousands

Adjustments required to reflect net cash used in operating activities:
Income and expenses not involving cash flows:
Depreciation and amortization		288			439
Long-term prepaid expenses		(2	)		(4	)
Exchange differences on cash and cash equivalents		(147	)		(34	)
Gain on adjustment of warrants to fair value		(625	)		(1,354	)
Gain on realization of long-term investment		(500	)		-
Share-based compensation		1,444			773
Warrant issuance costs		-			417
Interest and exchange rate differences on short-term deposits		(351	)		(440	)
Interest on loans		(1	)		292
		106			89

Changes in operating asset and liability items:
Decrease )increase(in prepaid expenses and other receivables		(776	)		848
Decrease in accounts payable and accruals		(1,384	)		(364	)
		(2,160	)		484
		(2,054	)		573

Supplemental information on interest received in cash		377			442

Supplemental information on interest paid in cash		167			477

Supplemental information on non-cash transaction - Initial establishment of right-of-use assets against lease liabilities		-			1,878

The accompanying notes are an integral part of these condensed consolidated interim financial statements.

F - 5

BioLineRx Ltd.

NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

(UNAUDITED)

NOTE 1 – GENERAL INFORMATION

General

BioLineRx Ltd. (“BioLineRx”), headquartered in Modi’in, Israel, was incorporated and commenced operations in April 2003.

BioLineRx and its subsidiaries (collectively, the “Company”) are engaged in the development of therapeutics, primarily in clinical-stages, with a focus on the field of oncology.

In February 2007, BioLineRx listed its ordinary shares on the Tel Aviv Stock Exchange (“TASE”) and they have been traded on the TASE since that time. Since July 2011, BioLineRx’s American Depositary Shares (“ADSs”) have also been traded on the NASDAQ Capital Market.

In March 2017, the Company acquired Agalimmune Ltd. (“Agalimmune”), a privately-held company incorporated in the United Kingdom, with a focus on the field of immuno-oncology.

Although the Company has generated significant revenues from a number of out-licensing transactions in the past, the Company cannot determine with reasonable certainty when and if it will have sustainable profits.

Approval of financial statements

The condensed consolidated interim financial statements of the Company as of June 30, 2019, and for the three and six months then ended, were approved by the Board of Directors on August 6, 2019, and signed on its behalf by the Chairman of the Board, the Chief Executive Officer and the Chief Financial Officer.

NOTE 2 – BASIS OF PREPARATION

The Company’s condensed consolidated interim financial statements as of June 30, 2019 and for the three and six months then ended (the “interim financial statements”) have been prepared in accordance with International Accounting Standard No. 34, “Interim Financial Reporting” (“IAS 34”). These interim financial statements, which are unaudited, do not include all disclosures necessary for a fair statement of financial position, results of operations, and cash flows in conformity with International Financial Reporting Standards (“IFRS”). The condensed consolidated interim financial statements should be read in conjunction with the Company’s annual financial statements as of December 31, 2018 and for the year then ended and their accompanying notes, which have been prepared in accordance with IFRS. The results of operations for the three and six months ended June 30, 2019 are not necessarily indicative of the results that may be expected for the entire fiscal year or for any other interim period.

F - 6

BioLineRx Ltd.

NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

(UNAUDITED)

NOTE 3 – SIGNIFICANT ACCOUNTING POLICIES

The accounting policies and calculation methods applied in the preparation of these interim financial statements are consistent with those applied in the preparation of the annual financial statements as of December 31, 2018 and for the year then ended, except for the adoption of IFRS No. 16, “Leases”.

Adjustments recognized on adoption of IFRS 16

The Company has adopted IFRS 16 retrospectively from January 1, 2019 but has not restated comparatives for the 2018 reporting period, as permitted under the specific transitional provisions in the standard. On adoption of IFRS 16, the Company recognized lease liabilities in relation to leases which had previously been classified as “operating leases” under the principles of IAS 17, “Leases.” These liabilities were measured at the present value of the remaining lease payments, discounted using the lessee’s incremental borrowing rate as of January 1, 2019. The remeasurements to the lease liabilities were recognized as adjustments to the related right-of-use assets immediately after the date of initial application. The associated right-of-use assets for property leases were measured on a retrospective basis as if the new rules had always been applied. Other right-of use assets were measured at the amount equal to the lease liability, adjusted by the amount of any prepaid or accrued lease payments relating to that lease recognized in the balance sheet as of December 31, 2018. The lessee’s weighted average incremental borrowing rate applied to the lease liabilities on January 1, 2019 was 15.1%.

	January 1,		June 30,
	2019		2019
Composition of right-of-use assets by type:
Property		1,552		1,485
Motor vehicles		326		231
Total right-of-use asset		1,878		1,716

Composition of lease liabilities recognized as of January 1, 2019:
Current lease liabilities			713
Non-current lease liabilities			1,165
			1,878

F - 7

BioLineRx Ltd.

NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

(UNAUDITED)

NOTE 3 – SIGNIFICANT ACCOUNTING POLICIES (cont.)

Practical expedients applied on adoption of IFRS 16

In applying IFRS 16 for the first time, the Company has used the following practical expedients permitted by the standard:

•

Use of a single discount rate to a portfolio of leases with reasonably similar characteristics;

•

Reliance on previous assessments on whether leases are onerous;

•

Accounting for operating leases with a remaining lease term of less than 12 months as of January 1, 2019, as short-term leases;

•

Exclusion of initial direct costs for the measurement of the right-of-use asset at the date of initial application;

•

Use of hindsight in determining the lease term where the contract contains options to extend or terminate the lease.

The Company has also elected not to reassess whether a contract is, or contains, a lease at the date of initial application. Instead, for contracts entered into before the transition date, the Company relied on its assessment made applying IAS 17 and IFRIC 4, “Determining whether an Arrangement contains a Lease.”

Other information relating to IFRS 16

As of June 30, 2019, the weighted average remaining lease term on the Company’s existing leases was 11.0 years for its property lease and 1.2 years for motor vehicle leases. Lease expense (substantially all of which is non-cash) for the six months ended June 30, 2019 amounted to $0.2 million. Cash paid for amounts included in the measurement of the operating lease liabilities for the six months ended June 30, 2019 was $0.1 million.

NOTE 4 – ISSUANCES OF SHARE CAPITAL AND WARRANTS

At-the-market (“ATM”) sales agreement with BTIG

In October 2017, the Company entered into an at-the-market (“ATM”) sales agreement with BTIG, LLC (“BTIG”), pursuant to which the Company may, at its sole discretion, offer and sell through BTIG, acting as sales agent, ADSs having an aggregate offering price of up to $30.0 million throughout the period during which the ATM facility remains in effect. The Company will pay BTIG a commission of 3.0% of the gross proceeds from the sale of ADSs under the facility. From the effective date of the agreement through June 30, 2019, 9,655,387 ADSs were sold under the program for total net proceeds of approximately $7.0 million, leaving an available balance under the facility of approximately $23.0 million as of June 30, 2019.

F - 8

BioLineRx Ltd.

NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

(UNAUDITED)

NOTE 4 – ISSUANCES OF SHARE CAPITAL AND WARRANTS (cont.)

Underwritten public offering

In February 2019, the Company completed an underwritten public offering of 28,000,000 of its ADSs and warrants to purchase 28,000,000 ADSs, at a public offering price of $0.55 per ADS and accompanying warrant. The warrants are exercisable immediately, expire five years from the date of issuance and have an exercise price of $0.75 per ADS. The offering raised a total of $15.4 million, with net proceeds of $14.1 million, after deducting fees and expenses. The amount of the offering consideration initially allocated to the warrants was $5.0 million. Total issuance costs initially allocated to the warrants were $0.4 million.

The warrants issued have been classified as a non-current financial liability due to a net settlement provision. This liability was initially recognized at its fair value on the date the contract was entered into and is subsequently accounted for at fair value at each balance sheet date. The fair value changes are charged to non-operating income and expense in the statement of comprehensive loss.

The fair value of the warrants is computed using the Black and Scholes option pricing model. The fair value of the warrants upon issuance was computed based on the then current price of an ADS, a risk-free interest rate of 2.50% and an average standard deviation of 62.8%. The fair value of the warrants as of June 30, 2019 was based on the then current price of an ADS, a risk-free interest rate of 1.76% and an average standard deviation of 65.2%. The change in fair value from the date of issuance through June 30, 2019 amounted to $1.3 million.

NOTE 5 – SHAREHOLDERS’ EQUITY

As of December 31, 2018 and June 30, 2019, share capital is composed of ordinary shares, as follows:

	Number of ordinary shares
	December 31,		June 30,
	2018		2019

Authorized share capital		250,000,000		250,000,000

Issued and paid-up share capital		114,933,144		147,183,744

	In USD and NIS
	December 31,		June 30,
	2018		2019

Authorized share capital (in NIS)		25,000,000		25,000,000

Issued and paid-up share capital (in NIS)		11,493,314		14,718,374

Issued and paid-up share capital (in USD)		3,109,746		4,000,676

NOTE 6 – EVENT SUBSEQUENT TO THE BALANCE SHEET DATE

On July 15, 2019, the Company implemented a change in the ratio of its ADSs to ordinary shares, from one ADS representing one ordinary share to a new ratio of one ADS representing 15 ordinary shares.

F - 9

EX-99 4 exhibit_3.htm REGISTRANT'S OPERATING AND FINANCIAL REVIEW AS OF JUNE 30, 2019.

Exhibit 3

OPERATING AND FINANCIAL REVIEW

You should read the following discussion of our operating and ﬁnancial condition and prospects in conjunction with the ﬁnancial statements and the notes thereto included elsewhere in this 6-K, as well as in our Annual Report on Form 20-F filed on March 28, 2019 (the “Annual Report”).

Forward Looking Statements

The following discussion contains “forward-looking statements,” including statements regarding expectations, beliefs, intentions or strategies for the future. These statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. In some cases, you can identify forward-looking statements by terms including “anticipates,” “believes,” “could,” “estimates,” “expects,” “intends,” “may,” “plans,” “potential,” “predicts,” “projects,” “should,” “will,” “would,” and similar expressions intended to identify forward-looking statements. Forward-looking statements reflect our current views with respect to future events and are based on assumptions, and are subject to risks and uncertainties. You should not put undue reliance on any forward-looking statements. Our actual results could differ materially from those discussed in the forward-looking statements. Factors that could cause or contribute to these differences include those listed below as well as those discussed in the Annual Report (particularly those in “Item 3. Key Information – Risk Factors”). Unless we are required to do so under U.S. federal securities laws or other applicable laws, we do not intend to update or revise any forward-looking statements.

Factors that could cause our actual results to differ materially from those expressed or implied in such forward-looking statements include, but are not limited to:

•

the initiation, timing, progress and results of our preclinical studies, clinical trials and other therapeutic candidate development efforts;

•

our ability to advance our therapeutic candidates into clinical trials or to successfully complete our preclinical studies or clinical trials;

•

our receipt of regulatory approvals for our therapeutic candidates, and the timing of other regulatory filings and approvals;

•

the clinical development, commercialization and market acceptance of our therapeutic candidates;

•

our ability to establish and maintain corporate collaborations;

•

our ability to integrate new therapeutic candidates and new personnel

•

the interpretation of the properties and characteristics of our therapeutic candidates and of the results obtained with our therapeutic candidates in preclinical studies or clinical trials;

•

the implementation of our business model and strategic plans for our business and therapeutic candidates;

•

the scope of protection we are able to establish and maintain for intellectual property rights covering our therapeutic candidates and our ability to operate our business without infringing the intellectual property rights of others;

•

estimates of our expenses, future revenues, capital requirements and our needs for additional financing;

•

risks related to changes in healthcare laws, rules and regulations in the United States or elsewhere;

•

competitive companies, technologies and our industry; and

•

statements as to the impact of the political and security situation in Israel on our business.

Overview

General

We are a clinical-stage biopharmaceutical development company with a strategic focus on oncology. Our current development and commercialization pipeline consists of two clinical-stage therapeutic candidates − BL-8040, a novel peptide for the treatment of hematological malignancies, solid tumors and stem cell mobilization, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, we have an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. We have generated our pipeline by systematically identifying, rigorously validating and in-licensing therapeutic candidates that we believe exhibit a high probability of therapeutic and commercial success. Our strategy includes commercializing our therapeutic candidates through out-licensing arrangements with biotechnology and pharmaceutical companies and evaluating, on a case by case basis, the commercialization of our therapeutic candidates independently.

Main Therapeutic Candidates

The following is a description of our main programs:

•

BL-8040 is a novel, short peptide that functions as a high-affinity antagonist for CXCR4, which we are developing for the treatment of solid tumors, acute myeloid leukemia, or AML, and stem-cell mobilization.

Solid tumors

➢

In January 2016, we entered into a collaboration with MSD (a tradename of Merck & Co., Inc., Kenilworth, New Jersey) in the field of cancer immunotherapy. Based on this collaboration, in September 2016 we initiated a Phase 2a study, known as the COMBAT/KEYNOTE-202 study, focusing on evaluating the safety and efficacy of BL-8040 in combination with KEYTRUDA^® (pembrolizumab), MSD’s anti-PD-1 therapy, in 37 patients with metastatic pancreatic adenocarcinoma. The study was an open-label, multicenter, single-arm trial designed to evaluate the clinical response, safety and tolerability of the combination of these therapies as well as multiple pharmacodynamic parameters, including the ability to improve infiltration of T-cells into the tumor and their reactivity. Top-line results showed that the combination demonstrated encouraging disease control and overall survival in patients with metastatic pancreatic cancer. In addition, assessment of patient biopsies supported BL-8040’s ability to induce infiltration of tumor-reactive T-cells into the tumor, while reducing the number of immune regulatory cells. In July 2018, we announced the expansion of the COMBAT/KEYNOTE-202 study under this collaboration to include a triple combination arm investigating the safety, tolerability and efficacy of BL-8040, KEYTRUDA and chemotherapy. We initiated this arm of the trial in December 2018. Top-line results from the new triple combination arm of the study are expected in the second half of 2019, with overall survival results expected in 2020.

➢

In August 2016, in the framework of an agreement with MD Anderson Cancer Center, we entered into an additional collaboration for the investigation of BL-8040 in combination with KEYTRUDA in pancreatic cancer. The focus of this study, in addition to assessing clinical response, is the mechanism of action by which both drugs might synergize, as well as multiple assessments to evaluate the biological anti-tumor effects induced by the combination. We are supplying BL-8040 for this Phase 2b study, which commenced in January 2017. Partial results from this study are anticipated in the second half of 2019, with top-line results expected in 2020.

➢

In September 2016, we entered into a collaboration with Genentech, Inc., or Genentech (a member of the Roche Group), in the framework of which both companies would carry out Phase 1b/2 studies investigating BL-8040 in combination with TECENTRIQ^® (atezolizumab), Genentech’s anti-PDL1 cancer immunotherapy, in various solid tumors and hematologic malignancies. The clinical study collaboration between us and Genentech is part of MORPHEUS, Roche’s novel cancer immunotherapy development platform. Genentech commenced a Phase 1b/2 study for the treatment of pancreatic cancer in July 2017, as well as a Phase 1b/2 study in gastric cancer in October 2017. These studies will evaluate the clinical response, safety and tolerability of the combination of these therapies, as well as multiple pharmacodynamic parameters. As we are not the sponsor of these studies, we do not have information about Genentech’s data publication plan for these BL-8040-related arms within the MORPHEUS platform.

AML

➢

During 2016, we completed and reported on a Phase 2a proof-of-concept trial for the treatment of relapsed or refractory acute myeloid leukemia, or r/r AML, which was conducted on 42 patients at six world-leading cancer research centers in the United States and at five premier sites in Israel. The study included both a dose-escalation and a dose-expansion phase. Results from the trial showed detailed, positive safety and response rate data for subjects treated with a combination of BL-8040 and high-dose cytarabine (Ara-C), or HiDAC. At the annual meeting of the European Hematology Association, or EHA, in June 2018, we presented positive overall survival data from the long-term follow-up part of this study. We continue to monitor long-term survival data for patients in the study and, in parallel, are planning our next clinical development steps in this indication.

➢

We are currently investigating BL-8040 as a consolidation treatment together with cytarabine (the current standard of care) for AML patients who have responded to standard induction treatment and are in complete remission and, in this regard, are conducting a significant Phase 2b trial in Germany, in collaboration with the German Study Alliance Leukemia Group. The Phase 2b trial is a double-blind, placebo-controlled, randomized, multi-center study aimed at assessing the efficacy of BL-8040 in addition to standard consolidation therapy in AML patients. Up to 194 patients will be enrolled in the trial. We continue to discuss with our collaboration partners the potential conduct of an interim analysis on this study based on various factors, including the occurrence of a minimum number of reported relapse events and/or exposure to provide a reasonable statistical powering for the analysis. Our current estimate for the timing of such potential interim analysis is in the second half of 2019; however, the occurrence of enough relapse events that would form the basis for a robust interim analysis is difficult to predict at this point in time. Top-line results from the trial are expected in 2021.

➢

In September 2017, we initiated a Phase 1b/2 trial in AML, known as the BATTLE trial, under the collaboration with Genentech referred to above in “― Solid tumors.” The trial was to have focused on the maintenance treatment of patients with intermediate- and high-risk AML who have achieved a complete response following induction and consolidation therapy. Following several protocol amendments designed to increase study recruitment, we consulted with Genentech regarding feasibility of completing the study, and jointly decided to terminate the trial in August 2019.

Stem cell mobilization

➢

In March 2015, we reported successful top-line safety and efficacy results from a Phase 1 safety and efficacy trial for the use of BL-8040 as a novel stem cell mobilization treatment for allogeneic bone marrow transplantation at Hadassah Medical Center in Jerusalem.

➢

In March 2016, we initiated a Phase 2 trial for BL-8040 in allogeneic stem cell transplantation, conducted in collaboration with the Washington University School of Medicine, Division of Oncology and Hematology. In May 2018, we announced positive top-line results of this study showing, among other things, that a single injection of BL-8040 mobilized sufficient amounts of CD34+ cells required for transplantation at a level of efficacy similar to that achieved by using 4-6 injections of G-CSF, the current standard of care.

➢

In December 2017, we commenced a randomized, controlled Phase 3 registrational trial for BL-8040, known as the GENESIS trial, for the mobilization of HSCs for autologous transplantation in patients with multiple myeloma. The trial began with a lead-in period for dose confirmation, which was to include 10-30 patients and then progress to the placebo-controlled main part, which is designed to include 177 patients in more than 25 centers. Following review of the positive results from treatment of the first 11 patients, the Data Monitoring Committee recommended that the lead-in part of the study should be stopped and that we should move immediately to the second part. Additional positive results from the lead-in period were reported at the annual meeting of the European Society for Blood and Marrow Transplantation held in March 2019, where it was announced that HSCs mobilized by BL-8040 in combination with G-CSF were successfully engrafted in all 11 patients. Top-line results of this randomized, placebo-controlled main part of the study are expected in the second half of 2020.

Other matters

➢

In addition to the above, we are currently conducting, or planning to conduct, a number of investigator-initiated, open-label studies in a variety of indications, to support the interest of the scientific and medical communities in exploring additional uses for BL-8040. These studies serve to further elucidate the mechanism of action for BL-8040.

➢

In September 2013, the FDA granted an Orphan Drug Designation to BL-8040 as a therapeutic for the treatment of AML; and in January 2014, the FDA granted an Orphan Drug Designation to BL-8040 as a treatment for stem cell mobilization. In January 2015, the FDA modified this Orphan Drug Designation for BL-8040 for use either as a single agent or in combination with G-CSF. In February 2019, the FDA granted Orphan Drug Designation to BL-8040 as a therapeutic for the treatment of pancreatic cancer.

•

AGI-134, a clinical therapeutic candidate in-licensed by Agalimmune, is a synthetic alpha-Gal glycolipid immunotherapy in development for solid tumors. AGI-134 harnesses the body’s pre-existing, highly abundant, anti-alpha-Gal antibodies to induce a hyper-acute, systemic, specific anti-tumor response to the patient’s own tumor neo-antigens. This response not only kills the tumor cells at the site of injection, but also brings about a durable, follow-on, anti-metastatic immune response. In August 2018, we initiated a Phase 1/2a clinical study for AGI-134 that is primarily designed to evaluate the safety and tolerability of AGI-134, given both as monotherapy and in combination with an immune checkpoint inhibitor, in unresectable metastatic solid tumors. The multi-center, open-label study is currently being carried out in the UK and Israel and, following recent approval by the FDA for our Investigational New Drug (IND) application, is expected to expand to the US by the first half of 2020. Initial safety results from the first part of the study are expected in the second half of 2019; initial efficacy results of the monotherapy arm from the second part of the study are expected by the end of 2020.

•

Our commercialized, legacy therapeutic product, BL-5010, is a customized, proprietary pen-like applicator containing a novel, acidic, aqueous solution for the non-surgical removal of skin lesions. In December 2014, we entered into an exclusive out-licensing arrangement with Perrigo Company plc, or Perrigo, for the rights to BL-5010 for over-the-counter, or OTC, indications in Europe, Australia and additional selected countries. In March 2016, Perrigo received CE Mark approval for BL-5010 as a novel OTC treatment for the non-surgical removal of warts. The commercial launch of this first OTC indication (warts/verrucas) commenced in Europe in the second quarter of 2016. Since then, Perrigo has invested in improving the product and expects to launch an improved version of the product during 2019.

Principal Partnering and Collaboration Agreements

Since December 2014 we have been collaborating with Novartis for the co-development of selected Israeli-sourced novel drug candidates.

In December 2014, we entered into an exclusive out-licensing arrangement with Perrigo Company plc, or Perrigo, for the rights to BL-5010 for over-the-counter or OTC indications in the territory of Europe, Australia and additional selected countries. We retain all OTC rights to BL-5010 in the United States and the rest of the world, as well as all non-OTC rights on a global basis. Perrigo fulfilled its obligation to launch a licensed product commercially in the Territory in 2016. In addition, Perrigo is obligated to use commercially reasonable best efforts to obtain regulatory approval in the Territory for at least one more OTC indication and to commercialize BL-5010 for that indication. Compensation by Perrigo for the exclusive license includes an agreed amount for each unit sold. We will have full access to all clinical and research and development data, as well as manufacturing data, generated during the performance of the development plan and may use these data in order to develop or license the product in other territories and fields of use where we retain the rights.

For information on our collaborations with Merck, Genentech and MD Anderson Cancer Center, see “― Main Therapeutic Candidates” above.

Funding

We have funded our operations primarily through the sale of equity securities (both in public and private offerings), funding received from a government body which previously was called the Office of the Chief Scientist of the Israeli Ministry of the Economy (OCS) (and which in 2016 was replaced by the newly-established Israel Innovation Authority, or IIA), payments received under out-licensing arrangements, and interest earned on investments. We expect to continue to fund our operations over the next several years through our existing cash resources, potential future milestone and royalty payments that we may receive from our existing out-licensing agreement, potential future upfront, milestone or royalty payments that we may receive from out-licensing transactions for our other therapeutic candidates, interest earned on our investments and additional capital to be raised through public or private equity offerings or debt ﬁnancings. As of June 30, 2019, we held $35.2 million of cash, cash equivalents and short-term bank deposits.

Recent Company Developments

AGI-134 – Regulatory

In May 2019, the FDA approved our IND application for AGI-134. This approval will enable us to expand the Phase 1/2a clinical study described above to the US by the first half of 2020.

Corporate matters

On December 3, 2018, we received written notice (the “Notification Letter”) from The Nasdaq Stock Market (“Nasdaq”) stating that we were not in compliance with the $1.00 minimum bid price requirement set forth in Nasdaq’s rules for continued listing on The Nasdaq Capital Market. On July 29, 2019, we received written notice from Nasdaq confirming that we had regained compliance with the $1.00 minimum bid price requirement.

On July 15, 2019, we implemented a change in the ratio of the Company’s ADSs to ordinary shares, from one ADS representing one ordinary share to a new ratio of one ADS representing 15 ordinary shares. The change in exchange ratio for the ADSs had the same effect as a 1-for-15 reverse stock split of the ADSs. In light of this change, all ADS amounts in this Operating and Financial Review have been stated based on the new ratio (i.e., subsequent to the 1-for-15 ratio change). The Company’s ordinary shares, which are not affected by the change, continue to trade on the Tel Aviv Stock Exchange.

Revenues

Our revenues to date have been generated primarily from milestone payments under previously existing out-licensing agreements.

We expect our revenues, if any, for the next several years to be derived primarily from future payments under our current out-licensing agreement with Perrigo and other potential collaboration arrangements, including future royalties on product sales.

Research and Development

Our research and development expenses consist primarily of salaries and related personnel expenses, fees paid to external service providers, up-front and milestone payments under our license agreements, patent-related legal fees, costs of preclinical studies and clinical trials, drug and laboratory supplies and costs for facilities and equipment. We primarily use external service providers to manufacture our product candidates for clinical trials and for the majority of our preclinical and clinical development work. We charge all research and development expenses to operations as they are incurred. We expect our research and development expense to remain our primary expense in the near future as we continue to develop our therapeutic candidates.

The following table identiﬁes our current major research and development projects:

Project	Status		Expected Near Term Milestones
	1.	Phase 2a study for relapsed or refractory AML completed	1. Follow-up for overall survival is ongoing; evaluation and decision regarding next clinical development steps
	2.	Phase 2b study in AML consolidation treatment line (BLAST) ongoing	2. Possible interim results in H2 2019; top-line results expected in 2021
	3.	Phase 2 study in allogeneic stem-cell mobilization completed	3. Follow-up on acute and chronic GvHD by H2 2019
BL-8040	4.	Phase 2a in pancreatic cancer under Merck collaboration (COMBAT/KEYNOTE-202) ongoing; top-line results from dual combination arm announced in October 2018	4. Top-line results from triple combination arm expected in H2 2019; overall survival results expected in 2020
	5.	Phase 2b study in pancreatic cancer, in collaboration with MD Anderson Cancer Center, ongoing	5. Partial results from this study are anticipated in H2 2019; top-line results expected in 2020
	6.	Phase 3 registration study in autologous stem-cell mobiliza-tion (GENESIS), ongoing	6. Top-line results from randomized, placebo-controlled main part of study expected in H2 2020

AGI-134	Phase 1/2a study commenced in August 2018		Initial safety results from part 1 of study in H2 2019; initial efficacy results of monotherapy arm from part 2 of study expected by end of 2020
BL-5010	Out-licensed to Perrigo; CE mark approval obtained; commercial launch of first OTC indication in Europe commenced		Launch of improved product during 2019; pursuit of potential out-licensing partner(s) for OTC and non-OTC rights still held by us

We expect that a large percentage of our research and development expense in the future will be incurred in support of our current and future preclinical and clinical development projects. Due to the inherently unpredictable nature of preclinical and clinical development processes and given the early stage of our preclinical product development projects, we are unable to estimate with any certainty the costs we will incur in the continued development of the therapeutic candidates in our pipeline for potential commercialization. Clinical development timelines, the probability of success and development costs can differ materially from expectations. We expect to continue to test our product candidates in preclinical studies for toxicology, safety and efficacy, and to conduct additional clinical trials for each product candidate. If we are not able to enter into an out-licensing arrangement with respect to any therapeutic candidate prior to the commencement of later stage clinical trials, we may fund the trials for the therapeutic candidate ourselves.

While we are currently focused on advancing each of our product development projects, our future research and development expenses will depend on the clinical success of each therapeutic candidate, as well as ongoing assessments of each therapeutic candidate’s commercial potential. In addition, we cannot forecast with any degree of certainty which therapeutic candidates may be subject to future out-licensing arrangements, when such out-licensing arrangements will be secured, if at all, and to what degree such arrangements would affect our development plans and capital requirements.

As we obtain results from clinical trials, we may elect to discontinue or delay clinical trials for certain therapeutic candidates or projects in order to focus our resources on more promising therapeutic candidates or projects. Completion of clinical trials by us or our licensees may take several years or more, but the length of time generally varies according to the type, complexity, novelty and intended use of a therapeutic candidate.

The cost of clinical trials may vary signiﬁcantly over the life of a project as a result of differences arising during clinical development, including, among others:

•

the number of sites included in the clinical trials;

•

the length of time required to enroll suitable patients;

•

the number of patients that participate in the clinical trials;

•

the duration of patient follow-up;

•

whether the patients require hospitalization or can be treated on an out-patient basis;

•

the development stage of the therapeutic candidate; and

•

the efficacy and safety proﬁle of the therapeutic candidate.

We expect our research and development expenses to remain our most significant cost as we continue the advancement of our clinical trials and preclinical product development projects and place significant emphasis on in-licensing new product candidates. The lengthy process of completing clinical trials and seeking regulatory approval for our product candidates requires expenditure of substantial resources. Any failure or delay in completing clinical trials, or in obtaining regulatory approvals, could cause a delay in generating product revenue and cause our research and development expenses to increase and, in turn, have a material adverse effect on our operations. Due to the factors set forth above, we are not able to estimate with any certainty when we would recognize any net cash inflows from our projects.

Sales and Marketing Expenses

Sales and marketing expenses consist primarily of compensation for employees in business development and marketing functions. Other signiﬁcant sales and marketing costs include costs for marketing and communication materials, professional fees for outside market research and consulting, legal services related to partnering transactions and travel costs.

General and Administrative Expenses

General and administrative expenses consist primarily of compensation for employees in executive and operational functions, including accounting, ﬁnance, legal, investor relations, information technology and human resources. Other signiﬁcant general and administration costs include facilities costs, professional fees for outside accounting and legal services, travel costs, insurance premiums and depreciation.

Non-Operating Expense and Income

Non-operating expense and income includes fair-value adjustments of liabilities on account of the warrants issued in equity financings we carried out in July 2017 and February 2019, as well as from debt financing we received in October 2018. These fair-value adjustments are highly influenced by our share price at each period end (revaluation date). Non-operating expense and income also includes the pro-rata share of issuance expenses from the placements related to the warrants, as well as the capital gain from realization of our investment in iPharma, a joint venture our holdings in which we sold in April 2018. Sales-based royalties and other revenue from the license agreement with Perrigo have also been included as part of non-operating income, as the out-licensed product is not an integral part of our strategy and the amounts are not material.

Financial Expense and Income

Financial expense and income consists of interest earned on our cash, cash equivalents and short-term bank deposits; interest on loans, bank fees and other transactional costs. In addition, it may also include gains/losses on foreign exchange hedging transactions, which we carry out from time to time to protect against a portion of our NIS-denominated expenses (primarily compensation) in relation to the dollar.

Significant Accounting Policies and Estimates

We describe our signiﬁcant accounting policies more fully in Note 2 to our consolidated ﬁnancial statements for the year ended December 31, 2018.

The discussion and analysis of our financial condition and results of operations is based on our financial statements, which we prepare in accordance with IFRS. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported revenues and expenses during the reporting periods. On an ongoing basis, we evaluate such estimates and judgments, including those described in greater detail below. We base our estimates on historical experience and on various assumptions that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

Results of Operations – Overview

Revenues

We did not record any revenues during each of the three- or six-month periods ended June 30, 2019 and 2018.

Cost of revenues

We did not record any cost of revenues during each of the three- or six-month periods ended June 30, 2019 and 2018.

Research and development expenses

At December 31, 2016, our drug development pipeline consisted of eight therapeutic candidates. During 2017, we terminated two therapeutic candidates in our pipeline and added one therapeutic candidate to the pipeline, so that our drug development pipeline as of December 31, 2017 consisted of seven therapeutic candidates. During 2018, we terminated four therapeutic candidates in our pipeline, so that our drug development pipeline as of December 31, 2018 and of the date of this report consists of three therapeutic candidates.

Operating Results Comparison between Periods

Revenues and cost of revenues

See discussion under “Results of Operations - Overview” above.

Research and development expenses

	Three months ended June 30,						Six months ended June 30,
	2018		2019		Increase (decrease)		2018		2019		Increase (decrease)
	(in thousands of U.S. dollars)
Research and development expenses, net		4,484		5,302		818		9,554		9,694		140

Comparison of three-month periods ending June 30, 2019 and 2018

Comparison of six-month periods ending June 30, 2019 and 2018

Research and development expenses for the six months ended June 30, 2019 were $9.7 million, an increase of $0.1 million, or 2%, compared to $9.6 million for the six months ended June 30, 2018. The small increase resulted primarily from higher expenses associated with the BL-8040 GENESIS and COMBAT clinical trials, offset by a decrease in expenses related to BL-1230, a project which was terminated, as well as a decrease in payroll and related expenses.

Sales and marketing expenses

	Three months ended June 30,							Six months ended June 30,
	2018		2019		Increase (decrease)			2018		2019		Increase (decrease)
	(in thousands of U.S. dollars)
Sales and marketing expenses		360		226		(134	)		844		482		(362	)

Comparison of three-month periods ending June 30, 2019 and 2018

Comparison of six-month periods ending June 30, 2019 and 2018

Sales and marketing expenses for the six months ended June 30, 2019 were $0.5 million, a decrease of $0.4 million, or 43%, compared to $0.9 million for the six months ended June 30, 2018. The decrease resulted primarily from a decrease in payroll and related expenses, including a one-time compensation payment in the 2018 period.

General and administrative expenses

	Three months ended June 30,						Six months ended June 30,
	2018		2019		Increase (decrease)		2018		2019		Increase (decrease)
	(in thousands of U.S. dollars)
General and administrative expenses		883		949		66		1,958		1,879		(79	)

Comparison of three-month periods ending June 30, 2019 and 2018

General and administrative expenses for the three months ended June 30, 2019 were $0.9 million, similar to the comparable period in 2018.

Comparison of six-month periods ending June 30, 2019 and 2018

General and administrative expenses for the six months ended June 30, 2019 were $1.9 million, similar to the comparable period in 2018.

Non-operating income (expenses), net

	Three months ended June 30,						Six months ended June 30,
	2018		2019		Increase (decrease)		2018		2019		Increase (decrease)
	(in thousands of U.S. dollars)
Non-operating income (expenses), net		663		1,261		598		1,125		921		(204	)

Comparison of three-month and six-month periods ending June 30, 2019 and 2018

Non-operating income for the three and six months ended June 30, 2019 primarily relate to fair-value adjustments of warrant liabilities on our balance sheet, offset by warrant offering expenses. Non-operating income for the six months ended June 30, 2018 primarily relate to fair-value adjustments of warrant liabilities on our balance sheet and the capital gain from realization of our investment in iPharma. These fair-value adjustments were highly influenced by our share price at each period end (revaluation date).

Financial income (expenses), net

	Three months ended June 30,									Six months ended June 30,
	2018			2019			Increase (decrease)			2018			2019			Increase (decrease)
	(in thousands of U.S. dollars)
Financial income		287			171			(116	)		462			381			(81	)
Financial expenses		(11	)		(440	)		(429	)		(217	)		(887	)		(670	)
Net financial income (expense)		276			(269	)		(545	)		245			(506	)		(751	)

Comparison of three-month periods ending June 30, 2019 and 2018

We recognized net financial expenses of $0.3 million for the three months ended June 30, 2019 compared to net financial income of $0.3 million for the three months ended June 30, 2018. Net financial expenses for the 2019 period primarily relate to interest paid on loans, offset by investment income earned on our bank deposits. Net financial income for the 2018 period primarily relates to investment income earned on our bank deposits, offset by losses recorded on foreign currency hedging transactions.

Comparison of six-month periods ending June 30, 2019 and 2018

We recognized net financial expense of $0.5 million for the six months ended June 30, 2019 compared to net financial income of $0.3 million for the six months ended June 30, 2018. Net financial expenses for the 2019 period primarily relate to interest paid on loans, offset by investment income earned on our bank deposits. Net financial income for the 2018 period primarily relates to investment income earned on our bank deposits, offset by losses recorded on foreign currency hedging transactions.

Liquidity and Capital Resources

Since inception, we have funded our operations primarily through public and private offerings of our equity securities, funding from the IIA, and payments received under our strategic licensing arrangements. At June 30, 2019, we held $35.2 million in cash, cash equivalents and short-term bank deposits. We have invested substantially all our available cash funds in short-term bank deposits.

Pursuant to our ATM Program with BTIG, LLC, or BTIG, we may sell, from time to time, and at our discretion, up to $30 million of our ADSs during the term of the program. During the six months ended June 30, 2019, we sold 281,079 ADSs under the program, resulting in net proceeds to BioLine of approximately $1.8 million (net of $56,000 in commissions paid to BTIG). As of the date of this report, we have an available balance under the program of approximately $23.0 million.

Net cash used in operating activities was $11.1 million for the six months ended June 30, 2019, compared with net cash used in operating activities of $13.0 million for the six months ended June 30, 2018. The $1.9 million decrease in net cash used in operating activities during the six-month period in 2019, compared to the six-month period in 2018, was primarily the result of changes in operating asset and liability items in the two periods, i.e., a decrease in prepaid expenses and other receivables in 2019 versus an increase in 2018, as well as a higher decrease in accounts payable and accruals in 2018.

Developing drugs, conducting clinical trials and commercializing products is expensive and we will need to raise substantial additional funds to achieve our strategic objectives. Although we believe our existing cash and other resources will be sufficient to fund our projected cash requirements into 2021, we will require signiﬁcant additional ﬁnancing in the future to fund our operations. Our future capital requirements will depend on many factors, including:

•

the progress and costs of our preclinical studies, clinical trials and other research and development activities;

•

the scope, prioritization and number of our clinical trials and other research and development programs;

•

the amount of revenues we receive under our collaboration or licensing arrangements;

•

the costs of the development and expansion of our operational infrastructure;

•

the costs and timing of obtaining regulatory approval of our therapeutic candidates;

•

the ability of our collaborators to achieve development milestones, marketing approval and other events or developments under our collaboration agreements;

•

the costs of ﬁling, prosecuting, enforcing and defending patent claims and other intellectual property rights;

•

the costs and timing of securing manufacturing arrangements for clinical or commercial production;

•

the costs of establishing sales and marketing capabilities or contracting with third parties to provide these capabilities for us;

•

the costs of acquiring or undertaking development and commercialization efforts for any future product candidates;

•

the magnitude of our general and administrative expenses;

•

any cost that we may incur under current and future licensing arrangements relating to our therapeutic candidates; and

Until we can generate signiﬁcant continuing revenues, we expect to satisfy our future cash needs through payments received under our collaborations, debt or equity ﬁnancings, or by out-licensing other product candidates. We cannot be certain that additional funding will be available to us on acceptable terms, or at all.

If funds are not available, we may be required to delay, reduce the scope of, or eliminate one or more of our research or development programs or our commercialization efforts.

Off-Balance Sheet Arrangements

Since inception, we have not entered into any transactions with unconsolidated entities whereby we have ﬁnancial guarantees, subordinated retained interests, derivative instruments or other contingent arrangements that expose us to material continuing risks, contingent liabilities, or any other obligations under a variable interest in an unconsolidated entity that provides us with ﬁnancing, liquidity, market risk or credit risk support.

Share and per-share information in ADSs

On July 15, 2019, we implemented a change in the ratio of our ADSs to ordinary shares, from one ADS representing one ordinary share to a new ratio of one ADS representing 15 ordinary shares. Accordingly, presented below, for the convenience of the reader, is share and per-share information in ADSs, on the basis of the new ADS ratio.

	Three months ended June 30,						Six months ended June 30,
	2018			2019			2018			2019
	(in U.S. dollars)
Loss per ADS – basic and diluted		(0.67	)		(0.57	)		(1.55	)		(1.25	)

	December 31, 2018		June 30, 2019
	(in number of ADSs)
Authorized share capital		16,666,667		16,666,667

Issued and paid-up capital		7,662,210		9,812,250

EX-101.INS 5 blrx-20190630.xml XBRL INSTANCE DOCUMENT 0001498403 2018-12-31 0001498403 ifrs-full:IssuedCapitalMember 2018-12-31 0001498403 ifrs-full:SharePremiumMember 2018-12-31 0001498403 ifrs-full:CapitalReserveMember 2018-12-31 0001498403 ifrs-full:RetainedEarningsMember 2018-12-31 0001498403 blrx:IsraelNewShekelsMember 2018-12-31 0001498403 blrx:BtigLlcMember 2017-10-31 0001498403 2019-01-01 2019-06-30 0001498403 2019-06-30 0001498403 2018-04-01 2018-06-30 0001498403 ifrs-full:IssuedCapitalMember 2019-01-01 2019-06-30 0001498403 ifrs-full:IssuedCapitalMember 2019-06-30 0001498403 ifrs-full:SharePremiumMember 2019-01-01 2019-06-30 0001498403 ifrs-full:SharePremiumMember 2019-06-30 0001498403 ifrs-full:CapitalReserveMember 2019-01-01 2019-06-30 0001498403 ifrs-full:CapitalReserveMember 2019-06-30 0001498403 ifrs-full:RetainedEarningsMember 2019-01-01 2019-06-30 0001498403 ifrs-full:RetainedEarningsMember 2019-06-30 0001498403 blrx:BtigLlcMember 2019-06-30 0001498403 blrx:BtigLlcMember 2019-01-01 2019-06-30 0001498403 blrx:AmericanDepositorySharesMember 2019-01-01 2019-06-30 0001498403 blrx:MiscellaneousOtherComprehensiveLossMember 2019-01-01 2019-06-30 0001498403 blrx:MiscellaneousOtherComprehensiveLossMember 2018-12-31 0001498403 blrx:MiscellaneousOtherComprehensiveLossMember 2019-06-30 0001498403 2018-01-01 2018-06-30 0001498403 2019-04-01 2019-06-30 0001498403 ifrs-full:IssuedCapitalMember 2018-01-01 2018-06-30 0001498403 ifrs-full:IssuedCapitalMember 2017-12-31 0001498403 ifrs-full:IssuedCapitalMember 2018-06-30 0001498403 ifrs-full:SharePremiumMember 2018-01-01 2018-06-30 0001498403 ifrs-full:SharePremiumMember 2017-12-31 0001498403 ifrs-full:SharePremiumMember 2018-06-30 0001498403 blrx:MiscellaneousOtherComprehensiveLossMember 2018-01-01 2018-06-30 0001498403 blrx:MiscellaneousOtherComprehensiveLossMember 2017-12-31 0001498403 blrx:MiscellaneousOtherComprehensiveLossMember 2018-06-30 0001498403 ifrs-full:CapitalReserveMember 2018-01-01 2018-06-30 0001498403 ifrs-full:CapitalReserveMember 2017-12-31 0001498403 ifrs-full:CapitalReserveMember 2018-06-30 0001498403 ifrs-full:RetainedEarningsMember 2018-01-01 2018-06-30 0001498403 ifrs-full:RetainedEarningsMember 2017-12-31 0001498403 ifrs-full:RetainedEarningsMember 2018-06-30 0001498403 2017-12-31 0001498403 2018-06-30 0001498403 blrx:IsraelNewShekelsMember 2019-06-30 0001498403 blrx:PublicOfferingMember 2019-02-28 0001498403 blrx:PublicOfferingMember 2019-02-01 2019-02-28 0001498403 blrx:AmericanDepositorySharesMember 2019-02-01 2019-02-28 0001498403 2019-01-02 0001498403 ifrs-full:MotorVehiclesMember 2019-01-01 2019-06-30 0001498403 ifrs-full:LandMember 2019-01-01 2019-06-30 0001498403 blrx:PublicOfferingMember us-gaap:WarrantMember 2019-02-01 2019-02-28 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure iso4217:ILS

3404000

4972000

5110000

5789000

41321000

3110000

250192000

11955000

-222520000

41782000

4001000

261522000

11835000

-234160000

-1416000

2836000

2920000

240682000

243883000

-1416000

10337000

11343000

-199558000

-210544000

52881000

46186000

-11640000

-4788000

-11640000

-10986000

-5485000

-10986000

-11067000

-13040000

-3122000

10772000

1534000

532000

15723000

2800000

1000

27000

-27000

1000

38000

-39000

773000

1444000

11327000

890000

10437000

2847000

83000

2764000

-27510000

-15000000

-24441000 -24385000

53000

76000

37000

15879000

7000000

2847000

15400000

5000000

-12055000

-5727000

-12356000

-6477000

921000 663000 1125000 1261000

381000

287000

462000

171000

887000

11000

217000

440000

-0.08

-0.05

-0.1

-0.04

139270178

106630704

106524332

145461598

439000

288000

-4000 -2000

-1354000

-625000

773000

1444000

-440000 -351000 89000 106000 -848000 776000

-364000

-1384000

484000 -2160000

573000

-2054000

1879000

883000

1958000

949000

482000

360000

844000

226000

9694000

4484000

9554000

5302000

BioLineRx Ltd. 0001498403 6-K 2019-06-30 false --12-31 Q2 2019 866000 -866000 399000 -399000

34000

147000

-34000

-147000

-1500000

500000

56233000

61958000

-222520000

-234160000

-1416000

11955000

11835000

250192000

261522000

3110000

4001000

14912000

20176000

8161000

11617000

1096000

1165000

7838000

6583000

323000 3938000

6751000

8559000

672000

713000

1363000

927000

4493000

4565000

895000

2395000

56233000

61958000

24255000

25751000

21972000

21928000

1716000

1878000

2227000

2047000

56000

60000

31978000

36207000

1339000

528000

488000

451000

26747000

30256000

417000

250000000

114933144

147183744

25000000000 25000000000 3109746000 11493314000 4000676000 14718374000

231000

326000

1485000

1552000

47000

1878000

110000

0.151

P1Y2M12D P11Y0M0D

1878000

30000000 0.03 23000000

28000000

28000000 Five years 0.75 14100000

0.0176

0.0250

0.652 0.628 0.55 9655387 100000 477000 167000

<div><div><div style="line-height: 1.25; font-weight: bold">NOTE 1 – GENERAL INFORMATION</div> <div style="line-height: 1.25"> <div style="line-height: 1.25"><br style="line-height: 1.25" /> </div> <div style="text-align: justify; line-height: 1.25"> <div> <table class="DSPFListTable" id="z162a98512be7411c81a819d56f3b9306" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000"> <tr> <td style="width: 51.05pt"><br /> </td> <td style="width: 19.85pt; vertical-align: top; font-weight: bold">a.</td> <td style="width: auto; vertical-align: top; text-align: justify"> <div style="font-weight: bold">General</div> </td> </tr> </table> </div> </div> <div style="line-height: 1.25"><br style="line-height: 1.25" /> </div> <div style="text-align: justify; margin-left: 70.9pt; line-height: 1.25">BioLineRx Ltd. (“BioLineRx”), headquartered in Modi’in, Israel, was incorporated and commenced operations in April 2003.</div> <div style="line-height: 1.25"><br style="line-height: 1.25" /> </div> <div style="text-align: justify; margin-left: 70.9pt; line-height: 1.25">BioLineRx and its subsidiaries (collectively, the “Company”) are engaged in the development of therapeutics, primarily in clinical-stages, with a focus on the field of oncology.</div> <div style="line-height: 1.25"><br style="line-height: 1.25" /> </div> <div style="text-align: justify; margin-left: 70.9pt; line-height: 1.25">In February 2007, BioLineRx listed its ordinary shares on the Tel Aviv Stock Exchange (“TASE”) and they have been traded on the TASE since that time. Since July 2011, BioLineRx’s American Depositary Shares (“ADSs”) have also been traded on the NASDAQ Capital Market.</div> <div style="line-height: 1.25"><br style="line-height: 1.25" /> </div> <div style="text-align: justify; margin-left: 70.9pt; line-height: 1.25">In March 2017, the Company acquired Agalimmune Ltd. (“Agalimmune”), a privately-held company incorporated in the United Kingdom, with a focus on the field of immuno-oncology.</div> <div style="line-height: 1.25"><br style="line-height: 1.25" /> </div> <div style="text-align: justify; margin-left: 70.9pt; line-height: 1.25">Although the Company has generated significant revenues from a number of out-licensing transactions in the past, the Company cannot determine with reasonable certainty when and if it will have sustainable profits.</div> <div style="line-height: 1.25"><br style="line-height: 1.25" /> </div> <div style="text-align: justify; line-height: 1.25"> <div> <table class="DSPFListTable" id="z4d888ec8366348dbb2231e1edbbe364a" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000"> <tr> <td style="width: 51.05pt"><br /> </td> <td style="width: 19.85pt; vertical-align: top; font-weight: bold">b.</td> <td style="width: auto; vertical-align: top; text-align: justify"> <div style="font-weight: bold">Approval of financial statements</div> </td> </tr> </table> </div> </div> <div style="line-height: 1.25"><br style="line-height: 1.25" /> </div> <div style="text-align: justify; margin-left: 70.9pt; line-height: 1.25">The condensed consolidated interim financial statements of the Company as of June 30, 2019, and for the three and six months then ended, were approved by the Board of Directors on August 6, 2019, and signed on its behalf by the Chairman of the Board, the Chief Executive Officer and the Chief Financial Officer.</div></div></div></div>

<div><div><div style="line-height: 1.25"><div style="line-height: 1.25"></div> <div style="line-height: 1.25; font-weight: bold">NOTE 2 – BASIS OF PREPARATION</div> <div style="line-height: 1.25"> </div> <div style="text-align: justify; margin-left: 51.05pt; line-height: 1.25">The Company’s condensed consolidated interim financial statements as of June 30, 2019 and for the three and six months then ended (the “interim financial statements”) have been prepared in accordance with International Accounting Standard No. 34, “Interim Financial Reporting” (“IAS 34”). These interim financial statements, which are unaudited, do not include all disclosures necessary for a fair statement of financial position, results of operations, and cash flows in conformity with International Financial Reporting Standards (“IFRS”). The condensed consolidated interim financial statements should be read in conjunction with the Company’s annual financial statements as of December 31, 2018 and for the year then ended and their accompanying notes, which have been prepared in accordance with IFRS. The results of operations for the three and six months ended June 30, 2019 are not necessarily indicative of the results that may be expected for the entire fiscal year or for any other interim period.</div></div></div></div>

<div><div><div style="line-height: 1.25"><div style="line-height: 1.25"></div> <div style="line-height: 1.25; font-weight: bold">NOTE 3 – SIGNIFICANT ACCOUNTING POLICIES</div> <div style="line-height: 1.25"> </div> <div style="text-align: justify; margin-left: 51.05pt; line-height: 1.25">The accounting policies and calculation methods applied in the preparation of these interim financial statements are consistent with those applied in the preparation of the annual financial statements as of December 31, 2018 and for the year then ended, except for the adoption of IFRS No. 16, “Leases”.</div> <div style="line-height: 1.25"><br style="line-height: 1.25" /> </div> <div style="text-align: justify; line-height: 1.25"> <div> <table class="DSPFListTable" id="z2258e14b1c3d4df2aa9c6812495744bf" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000"> <tr> <td style="width: 51.05pt"><br /> </td> <td style="width: 19.85pt; vertical-align: top; font-weight: bold">a.</td> <td style="width: auto; vertical-align: top; text-align: justify"> <div style="font-weight: bold">Adjustments recognized on adoption of IFRS 16</div> </td> </tr> </table> </div> </div> <div style="line-height: 1.25"><br style="line-height: 1.25" /> </div> <div style="text-align: justify; margin-left: 70.9pt; line-height: 1.25">The Company has adopted IFRS 16 retrospectively from January 1, 2019 but has not restated comparatives for the 2018 reporting period, as permitted under the specific transitional provisions in the standard. On adoption of IFRS 16, the Company recognized lease liabilities in relation to leases which had previously been classified as “operating leases” under the principles of IAS 17, “Leases.” These liabilities were measured at the present value of the remaining lease payments, discounted using the lessee’s incremental borrowing rate as of January 1, 2019. The remeasurements to the lease liabilities were recognized as adjustments to the related right-of-use assets immediately after the date of initial application. The associated right-of-use assets for property leases were measured on a retrospective basis as if the new rules had always been applied. Other right-of use assets were measured at the amount equal to the lease liability, adjusted by the amount of any prepaid or accrued lease payments relating to that lease recognized in the balance sheet as of December 31, 2018. The lessee’s weighted average incremental borrowing rate applied to the lease liabilities on January 1, 2019 was 15.1%.</div> <div style="line-height: 1.25"><br style="line-height: 1.25" /> </div> <table id="z83469f45cfea4f96890d537d84380453" border="0" cellpadding="0" cellspacing="0" align="right" style="width: 91%; color: #000000; font: 10pt Times New Roman, Times, serif; text-align: left"> <tr> <td style="vertical-align: bottom; padding-bottom: 2px; vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; vertical-align: bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom"> <div style="line-height: 1.25"> <div style="text-align: center; line-height: 1.25; font-weight: bold">January 1,</div> </div> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap; vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; vertical-align: bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom"> <div style="line-height: 1.25"> <div style="text-align: center; line-height: 1.25; font-weight: bold">June 30,</div> </div> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap; vertical-align: bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; padding-bottom: 2px; vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; vertical-align: bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom"> <div style="line-height: 1.25"> <div style="text-align: center; line-height: 1.25; font-weight: bold"> 2019</div> </div> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap; vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; vertical-align: bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom"> <div style="line-height: 1.25"> <div style="text-align: center; line-height: 1.25; font-weight: bold">2019</div> </div> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap; vertical-align: bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom"> <div style="line-height: 1.25">Composition of right-of-use assets by type:</div> </td> <td colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom"> </td> <td colspan="2" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap; vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom"> </td> <td colspan="2" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap; vertical-align: bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; background-color: rgb(255, 255, 255); vertical-align: bottom"> <div style="text-indent: 14.2pt; line-height: 1.25">Property</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(255, 255, 255); vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(255, 255, 255); vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(255, 255, 255); vertical-align: bottom"> <div style="line-height: 1.25">1,552</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(255, 255, 255); white-space: nowrap; vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(255, 255, 255); vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(255, 255, 255); vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(255, 255, 255); vertical-align: bottom"> <div style="line-height: 1.25">1,485</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(255, 255, 255); white-space: nowrap; vertical-align: bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: rgb(204, 238, 255); vertical-align: bottom"> <div style="text-indent: 14.2pt; line-height: 1.25">Motor vehicles</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: rgb(0, 0, 0) 2px solid; background-color: rgb(204, 238, 255); vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: rgb(0, 0, 0) 2px solid; background-color: rgb(204, 238, 255); vertical-align: bottom"> <div style="line-height: 1.25"> <div style="line-height: 1.25">326</div> </div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap; vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: rgb(0, 0, 0) 2px solid; background-color: rgb(204, 238, 255); vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: rgb(0, 0, 0) 2px solid; background-color: rgb(204, 238, 255); vertical-align: bottom"> <div style="line-height: 1.25"> <div style="line-height: 1.25">231</div> </div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap; vertical-align: bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: rgb(255, 255, 255); vertical-align: bottom"> <div style="text-indent: 28.35pt; line-height: 1.25">Total right-of-use asset</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(255, 255, 255); vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: rgb(0, 0, 0) 2px solid; background-color: rgb(255, 255, 255); vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: rgb(0, 0, 0) 2px solid; background-color: rgb(255, 255, 255); vertical-align: bottom"> <div style="line-height: 1.25"> <div style="line-height: 1.25">1,878</div> </div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(255, 255, 255); white-space: nowrap; vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(255, 255, 255); vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: rgb(0, 0, 0) 2px solid; background-color: rgb(255, 255, 255); vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: rgb(0, 0, 0) 2px solid; background-color: rgb(255, 255, 255); vertical-align: bottom"> <div style="line-height: 1.25"> <div style="line-height: 1.25">1,716</div> </div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(255, 255, 255); white-space: nowrap; vertical-align: bottom"> </td> </tr> </table> <div style="line-height: 1.25; clear: both"><br style="line-height: 1.25" /> </div> <table id="z62bcf0e410bd4ba7a264d5799588b83e" border="0" cellpadding="0" cellspacing="0" align="right" style="width: 91%; color: #000000; font: 10pt Times New Roman, Times, serif; text-align: left"> <tr> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 84%; vertical-align: bottom"> <div style="line-height: 1.25">Composition of lease liabilities recognized as of January 1, 2019:</div> </td> <td colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom"> </td> <td colspan="2" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%; white-space: nowrap; vertical-align: bottom"> </td> <td colspan="1" style="background-color: #FFFFFF; vertical-align: bottom; white-space: nowrap; width: 4%"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 84%; background-color: rgb(255, 255, 255); vertical-align: bottom"> <div style="text-indent: 14.2pt; line-height: 1.25">Current lease liabilities</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(255, 255, 255); vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(255, 255, 255); vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(255, 255, 255); vertical-align: bottom"> <div style="line-height: 1.25">713</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(255, 255, 255); white-space: nowrap; vertical-align: bottom"> </td> <td colspan="1" style="background-color: #FFFFFF; vertical-align: bottom; white-space: nowrap; width: 4%"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 84%; padding-bottom: 2px; background-color: rgb(204, 238, 255); vertical-align: bottom"> <div style="text-indent: 14.2pt; line-height: 1.25">Non-current lease liabilities</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: rgb(0, 0, 0) 2px solid; background-color: rgb(204, 238, 255); vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: rgb(0, 0, 0) 2px solid; background-color: rgb(204, 238, 255); vertical-align: bottom"> <div style="line-height: 1.25"> <div style="line-height: 1.25">1,165</div> </div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap; vertical-align: bottom"> </td> <td colspan="1" style="background-color: #FFFFFF; vertical-align: bottom; white-space: nowrap; width: 4%; padding: 0px 0px 2px"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 84%; padding-bottom: 2px; background-color: rgb(255, 255, 255); vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(255, 255, 255); vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: rgb(0, 0, 0) 2px solid; background-color: rgb(255, 255, 255); vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: rgb(0, 0, 0) 2px solid; background-color: rgb(255, 255, 255); vertical-align: bottom"> <div style="line-height: 1.25"> <div style="line-height: 1.25">1,878</div> </div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(255, 255, 255); white-space: nowrap; vertical-align: bottom"> </td> <td colspan="1" style="background-color: #FFFFFF; vertical-align: bottom; white-space: nowrap; width: 4%; padding: 0px 0px 2px"> </td> </tr> </table> <div style="line-height: 1.25; clear: both"><br style="line-height: 1.25" /> </div> <div style="line-height: 1.25"> </div> <div style="text-align: justify; line-height: 1.25"> <div> <table class="DSPFListTable" id="zd572949c084e443f80a16c57f424b6c2" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000"> <tr> <td style="width: 51.05pt"><br /> </td> <td style="width: 19.85pt; vertical-align: top; font-weight: bold">b.</td> <td style="width: auto; vertical-align: top; text-align: justify"> <div style="font-weight: bold">Practical expedients applied on adoption of IFRS 16</div> </td> </tr> </table> </div> </div> <div style="line-height: 1.25"><br style="line-height: 1.25" /> </div> <div style="text-align: justify; margin-left: 70.9pt; line-height: 1.25">In applying IFRS 16 for the first time, the Company has used the following practical expedients permitted by the standard:</div> <div style="line-height: 1.25"><br style="line-height: 1.25" /> </div> <div style="text-align: justify; line-height: 1.25"> <div> <table class="DSPFListTable" id="z8ff79469b66040499d012d227b8fbcfd" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000"> <tr> <td style="width: 88.9pt"><br /> </td> <td style="width: 18pt; vertical-align: top">•</td> <td style="width: auto; vertical-align: top; text-align: justify"> <div>Use of a single discount rate to a portfolio of leases with reasonably similar characteristics;</div> </td> </tr> </table> </div> </div> <div style="text-align: justify; line-height: 1.25"> <div> <table class="DSPFListTable" id="z56d14db2e8a54eb88f877208d30648f4" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000"> <tr> <td style="width: 88.9pt"><br /> </td> <td style="width: 18pt; vertical-align: top">•</td> <td style="width: auto; vertical-align: top; text-align: justify"> <div>Reliance on previous assessments on whether leases are onerous;</div> </td> </tr> </table> </div> </div> <div style="text-align: justify; line-height: 1.25"> <div> <table class="DSPFListTable" id="zeaccab9c182346609e44504802b34c7b" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000"> <tr> <td style="width: 88.9pt"><br /> </td> <td style="width: 18pt; vertical-align: top">•</td> <td style="width: auto; vertical-align: top; text-align: justify"> <div>Accounting for operating leases with a remaining lease term of less than 12 months as of January 1, 2019, as short-term leases;</div> </td> </tr> </table> </div> </div> <div style="text-align: justify; line-height: 1.25"> <div> <table class="DSPFListTable" id="z4a3a91bc6fcc46f5982dc6f5cfcc73ee" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000"> <tr> <td style="width: 88.9pt"><br /> </td> <td style="width: 18pt; vertical-align: top">•</td> <td style="width: auto; vertical-align: top; text-align: justify"> <div>Exclusion of initial direct costs for the measurement of the right-of-use asset at the date of initial application;</div> </td> </tr> </table> </div> </div> <div style="text-align: justify; line-height: 1.25"> <div> <table class="DSPFListTable" id="z7dde3a022f0440ca839105107035449c" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000"> <tr> <td style="width: 88.9pt"><br /> </td> <td style="width: 18pt; vertical-align: top">•</td> <td style="width: auto; vertical-align: top; text-align: justify"> <div>Use of hindsight in determining the lease term where the contract contains options to extend or terminate the lease.</div> </td> </tr> </table> </div> </div> <div style="line-height: 1.25"><br style="line-height: 1.25" /> </div> <div style="text-align: justify; margin-left: 70.9pt; line-height: 1.25">The Company has also elected not to reassess whether a contract is, or contains, a lease at the date of initial application. Instead, for contracts entered into before the transition date, the Company relied on its assessment made applying IAS 17 and IFRIC 4, “Determining whether an Arrangement contains a Lease.”</div> <div style="line-height: 1.25"><br style="line-height: 1.25" /> </div> <div style="text-align: justify; line-height: 1.25"> <div> <table class="DSPFListTable" id="zce4f428f92d34286b79082bbdfd6af19" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000"> <tr> <td style="width: 51.05pt"><br /> </td> <td style="width: 19.85pt; vertical-align: top; font-weight: bold">c.</td> <td style="width: auto; vertical-align: top; text-align: justify"> <div style="font-weight: bold">Other information relating to IFRS 16</div> </td> </tr> </table> </div> </div> <div style="line-height: 1.25"><br style="line-height: 1.25" /> </div> <div style="text-align: justify; margin-left: 70.9pt; line-height: 1.25">As of June 30, 2019, the weighted average remaining lease term on the Company’s existing leases was 11.0 years for its property lease and 1.2 years for motor vehicle leases. Lease expense (substantially all of which is non-cash) for the six months ended June 30, 2019 amounted to $0.2 million. Cash paid for amounts included in the measurement of the operating lease liabilities for the six months ended June 30, 2019 was $0.1 million.</div></div></div></div>

<div><div style="line-height: 1.25; font-weight: bold">NOTE 5 – SHAREHOLDERS’ EQUITY</div> <div style="line-height: 1.25"> </div> <div style="text-align: justify; margin-left: 51.05pt; line-height: 1.25">As of December 31, 2018 and June 30, 2019, share capital is composed of ordinary shares, as follows:</div> <div style="line-height: 1.25"><br style="line-height: 1.25" /> </div> <table id="zbc787afb30f745778a28afad042d05e7" border="0" cellpadding="0" cellspacing="0" align="right" style="width: 92%; color: #000000; font: 10pt Times New Roman, Times, serif; text-align: left"> <tr> <td style="vertical-align: top; padding-bottom: 2px; vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; vertical-align: bottom"> </td> <td colspan="6" style="vertical-align: top; border-bottom: #000000 2px solid; vertical-align: bottom"> <div style="line-height: 1.25"> <div style="text-align: center; line-height: 1.25; font-weight: bold">Number of ordinary shares</div> </div> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap; vertical-align: bottom"> </td> </tr> <tr> <td style="vertical-align: top; padding-bottom: 2px; vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; vertical-align: bottom"> </td> <td colspan="2" style="vertical-align: top; border-bottom: #000000 2px solid; vertical-align: bottom"> <div style="line-height: 1.25"> <div style="text-align: center; line-height: 1.25; font-weight: bold">December 31,</div> </div> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap; vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; vertical-align: bottom"> </td> <td colspan="2" style="vertical-align: top; border-bottom: #000000 2px solid; vertical-align: bottom"> <div style="line-height: 1.25"> <div style="text-align: center; line-height: 1.25; font-weight: bold">June 30,</div> </div> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap; vertical-align: bottom"> </td> </tr> <tr> <td style="vertical-align: top; padding-bottom: 2px; vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; vertical-align: bottom"> </td> <td colspan="2" style="vertical-align: top; border-bottom: #000000 2px solid; vertical-align: bottom"> <div style="line-height: 1.25"> <div style="text-align: center; line-height: 1.25; font-weight: bold"> 2018</div> </div> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap; vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; vertical-align: bottom"> </td> <td colspan="2" style="vertical-align: top; border-bottom: #000000 2px solid; vertical-align: bottom"> <div style="line-height: 1.25"> <div style="text-align: center; line-height: 1.25; font-weight: bold">2019</div> </div> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap; vertical-align: bottom"> </td> </tr> <tr> <td style="vertical-align: top; vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; vertical-align: bottom"> </td> <td colspan="2" style="vertical-align: top; vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; vertical-align: bottom"> </td> <td colspan="2" style="vertical-align: top; vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom"> </td> </tr> <tr> <td style="vertical-align: top; width: 76%; padding-bottom: 4px; background-color: rgb(204, 238, 255); vertical-align: bottom"> <div style="line-height: 1.25">Authorized share capital</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: rgb(0, 0, 0) 4px double; background-color: rgb(204, 238, 255); vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: rgb(0, 0, 0) 4px double; background-color: rgb(204, 238, 255); vertical-align: bottom"> <div style="line-height: 1.25"> <div style="line-height: 1.25">250,000,000</div> </div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap; vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: rgb(0, 0, 0) 4px double; background-color: rgb(204, 238, 255); vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: rgb(0, 0, 0) 4px double; background-color: rgb(204, 238, 255); vertical-align: bottom"> <div style="line-height: 1.25"> <div style="line-height: 1.25">250,000,000</div> </div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap; vertical-align: bottom"> </td> </tr> <tr> <td style="vertical-align: top; width: 76%; background-color: rgb(255, 255, 255); vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(255, 255, 255); vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(255, 255, 255); vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(255, 255, 255); vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(255, 255, 255); white-space: nowrap; vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(255, 255, 255); vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(255, 255, 255); vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(255, 255, 255); vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(255, 255, 255); white-space: nowrap; vertical-align: bottom"> </td> </tr> <tr> <td style="vertical-align: top; width: 76%; padding-bottom: 4px; background-color: rgb(204, 238, 255); vertical-align: bottom"> <div style="line-height: 1.25">Issued and paid-up share capital</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: rgb(0, 0, 0) 4px double; background-color: rgb(204, 238, 255); vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: rgb(0, 0, 0) 4px double; background-color: rgb(204, 238, 255); vertical-align: bottom"> <div style="line-height: 1.25"> <div style="line-height: 1.25">114,933,144</div> </div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap; vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: rgb(0, 0, 0) 4px double; background-color: rgb(204, 238, 255); vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: rgb(0, 0, 0) 4px double; background-color: rgb(204, 238, 255); vertical-align: bottom"> <div style="line-height: 1.25"> <div style="line-height: 1.25">147,183,744</div> </div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap; vertical-align: bottom"> </td> </tr> </table> <div style="clear: both"><br /> </div> <table id="z56b5cbd86415496c886f02628b1c1d7c" border="0" cellpadding="0" cellspacing="0" align="right" style="width: 92%; color: #000000; font: 10pt Times New Roman, Times, serif; text-align: left"> <tr> <td style="vertical-align: top; padding-bottom: 2px; vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; vertical-align: bottom"> </td> <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom"> <div style="line-height: 1.25"> <div style="text-align: center; line-height: 1.25; font-weight: bold">In USD and NIS</div> </div> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap; vertical-align: bottom"> </td> </tr> <tr> <td style="vertical-align: top; padding-bottom: 2px; vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; vertical-align: bottom"> </td> <td colspan="2" style="vertical-align: top; border-bottom: #000000 2px solid; vertical-align: bottom"> <div style="line-height: 1.25"> <div style="text-align: center; line-height: 1.25; font-weight: bold">December 31,</div> </div> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap; vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; vertical-align: bottom"> </td> <td colspan="2" style="vertical-align: top; border-bottom: #000000 2px solid; vertical-align: bottom"> <div style="line-height: 1.25"> <div style="text-align: center; line-height: 1.25; font-weight: bold">June 30,</div> </div> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap; vertical-align: bottom"> </td> </tr> <tr> <td style="vertical-align: top; padding-bottom: 2px; vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; vertical-align: bottom"> </td> <td colspan="2" style="vertical-align: top; border-bottom: #000000 2px solid; vertical-align: bottom"> <div style="line-height: 1.25"> <div style="text-align: center; line-height: 1.25; font-weight: bold"> 2018</div> </div> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap; vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; vertical-align: bottom"> </td> <td colspan="2" style="vertical-align: top; border-bottom: #000000 2px solid; vertical-align: bottom"> <div style="line-height: 1.25"> <div style="text-align: center; line-height: 1.25; font-weight: bold">2019</div> </div> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap; vertical-align: bottom"> </td> </tr> <tr> <td style="vertical-align: top; vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; vertical-align: bottom"> </td> <td colspan="2" style="vertical-align: top; vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; vertical-align: bottom"> </td> <td colspan="2" style="vertical-align: top; vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom"> </td> </tr> <tr> <td style="vertical-align: top; width: 76%; padding-bottom: 4px; background-color: rgb(204, 238, 255); vertical-align: bottom"> <div style="line-height: 1.25">Authorized share capital (in NIS)</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: rgb(0, 0, 0) 4px double; background-color: rgb(204, 238, 255); vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: rgb(0, 0, 0) 4px double; background-color: rgb(204, 238, 255); vertical-align: bottom"> <div style="line-height: 1.25"> <div style="line-height: 1.25">25,000,000</div> </div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap; vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: rgb(0, 0, 0) 4px double; background-color: rgb(204, 238, 255); vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: rgb(0, 0, 0) 4px double; background-color: rgb(204, 238, 255); vertical-align: bottom"> <div style="line-height: 1.25"> <div style="line-height: 1.25">25,000,000</div> </div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap; vertical-align: bottom"> </td> </tr> <tr> <td style="vertical-align: top; width: 76%; background-color: rgb(255, 255, 255); vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(255, 255, 255); vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(255, 255, 255); vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(255, 255, 255); vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(255, 255, 255); white-space: nowrap; vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(255, 255, 255); vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(255, 255, 255); vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(255, 255, 255); vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(255, 255, 255); white-space: nowrap; vertical-align: bottom"> </td> </tr> <tr> <td style="vertical-align: top; width: 76%; padding-bottom: 4px; background-color: rgb(204, 238, 255); vertical-align: bottom"> <div style="line-height: 1.25">Issued and paid-up share capital (in NIS)</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: rgb(0, 0, 0) 4px double; background-color: rgb(204, 238, 255); vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: rgb(0, 0, 0) 4px double; background-color: rgb(204, 238, 255); vertical-align: bottom"> <div style="line-height: 1.25"> <div style="line-height: 1.25">11,493,314</div> </div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap; vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: rgb(0, 0, 0) 4px double; background-color: rgb(204, 238, 255); vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: rgb(0, 0, 0) 4px double; background-color: rgb(204, 238, 255); vertical-align: bottom"> <div style="line-height: 1.25"> <div style="line-height: 1.25">14,718,374</div> </div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap; vertical-align: bottom"> </td> </tr> <tr> <td style="vertical-align: top; width: 76%; background-color: rgb(255, 255, 255); vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(255, 255, 255); vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(255, 255, 255); vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(255, 255, 255); vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(255, 255, 255); white-space: nowrap; vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(255, 255, 255); vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(255, 255, 255); vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(255, 255, 255); vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(255, 255, 255); white-space: nowrap; vertical-align: bottom"> </td> </tr> <tr> <td style="vertical-align: top; width: 76%; padding-bottom: 4px; background-color: rgb(204, 238, 255); vertical-align: bottom"> <div style="line-height: 1.25">Issued and paid-up share capital (in USD)</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: rgb(0, 0, 0) 4px double; background-color: rgb(204, 238, 255); vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: rgb(0, 0, 0) 4px double; background-color: rgb(204, 238, 255); vertical-align: bottom"> <div style="line-height: 1.25"> <div style="line-height: 1.25">3,109,746</div> </div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap; vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: rgb(0, 0, 0) 4px double; background-color: rgb(204, 238, 255); vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: rgb(0, 0, 0) 4px double; background-color: rgb(204, 238, 255); vertical-align: bottom"> <div style="line-height: 1.25"> <div style="line-height: 1.25">4,000,676</div></div></td></tr></table></div>

<div><div style="text-align: justify; margin-left: 51.05pt; line-height: 1.25">As of December 31, 2018 and June 30, 2019, share capital is composed of ordinary shares, as follows:</div> <div style="line-height: 1.25"><br style="line-height: 1.25" /> </div> <table id="zbc787afb30f745778a28afad042d05e7" border="0" cellpadding="0" cellspacing="0" align="right" style="width: 92%; color: #000000; font: 10pt Times New Roman, Times, serif; text-align: left"> <tr> <td style="vertical-align: top; padding-bottom: 2px; vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; vertical-align: bottom"> </td> <td colspan="6" style="vertical-align: top; border-bottom: #000000 2px solid; vertical-align: bottom"> <div style="line-height: 1.25"> <div style="text-align: center; line-height: 1.25; font-weight: bold">Number of ordinary shares</div> </div> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap; vertical-align: bottom"> </td> </tr> <tr> <td style="vertical-align: top; padding-bottom: 2px; vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; vertical-align: bottom"> </td> <td colspan="2" style="vertical-align: top; border-bottom: #000000 2px solid; vertical-align: bottom"> <div style="line-height: 1.25"> <div style="text-align: center; line-height: 1.25; font-weight: bold">December 31,</div> </div> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap; vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; vertical-align: bottom"> </td> <td colspan="2" style="vertical-align: top; border-bottom: #000000 2px solid; vertical-align: bottom"> <div style="line-height: 1.25"> <div style="text-align: center; line-height: 1.25; font-weight: bold">June 30,</div> </div> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap; vertical-align: bottom"> </td> </tr> <tr> <td style="vertical-align: top; padding-bottom: 2px; vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; vertical-align: bottom"> </td> <td colspan="2" style="vertical-align: top; border-bottom: #000000 2px solid; vertical-align: bottom"> <div style="line-height: 1.25"> <div style="text-align: center; line-height: 1.25; font-weight: bold"> 2018</div> </div> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap; vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; vertical-align: bottom"> </td> <td colspan="2" style="vertical-align: top; border-bottom: #000000 2px solid; vertical-align: bottom"> <div style="line-height: 1.25"> <div style="text-align: center; line-height: 1.25; font-weight: bold">2019</div> </div> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap; vertical-align: bottom"> </td> </tr> <tr> <td style="vertical-align: top; vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; vertical-align: bottom"> </td> <td colspan="2" style="vertical-align: top; vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; vertical-align: bottom"> </td> <td colspan="2" style="vertical-align: top; vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom"> </td> </tr> <tr> <td style="vertical-align: top; width: 76%; padding-bottom: 4px; background-color: rgb(204, 238, 255); vertical-align: bottom"> <div style="line-height: 1.25">Authorized share capital</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: rgb(0, 0, 0) 4px double; background-color: rgb(204, 238, 255); vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: rgb(0, 0, 0) 4px double; background-color: rgb(204, 238, 255); vertical-align: bottom"> <div style="line-height: 1.25"> <div style="line-height: 1.25">250,000,000</div> </div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap; vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: rgb(0, 0, 0) 4px double; background-color: rgb(204, 238, 255); vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: rgb(0, 0, 0) 4px double; background-color: rgb(204, 238, 255); vertical-align: bottom"> <div style="line-height: 1.25"> <div style="line-height: 1.25">250,000,000</div> </div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap; vertical-align: bottom"> </td> </tr> <tr> <td style="vertical-align: top; width: 76%; background-color: rgb(255, 255, 255); vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(255, 255, 255); vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(255, 255, 255); vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(255, 255, 255); vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(255, 255, 255); white-space: nowrap; vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(255, 255, 255); vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(255, 255, 255); vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(255, 255, 255); vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(255, 255, 255); white-space: nowrap; vertical-align: bottom"> </td> </tr> <tr> <td style="vertical-align: top; width: 76%; padding-bottom: 4px; background-color: rgb(204, 238, 255); vertical-align: bottom"> <div style="line-height: 1.25">Issued and paid-up share capital</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: rgb(0, 0, 0) 4px double; background-color: rgb(204, 238, 255); vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: rgb(0, 0, 0) 4px double; background-color: rgb(204, 238, 255); vertical-align: bottom"> <div style="line-height: 1.25"> <div style="line-height: 1.25">114,933,144</div> </div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap; vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: rgb(0, 0, 0) 4px double; background-color: rgb(204, 238, 255); vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: rgb(0, 0, 0) 4px double; background-color: rgb(204, 238, 255); vertical-align: bottom"> <div style="line-height: 1.25"> <div style="line-height: 1.25">147,183,744</div> </div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap; vertical-align: bottom"> </td> </tr> </table> <div style="clear: both"><br /> </div> <table id="z56b5cbd86415496c886f02628b1c1d7c" border="0" cellpadding="0" cellspacing="0" align="right" style="width: 92%; color: #000000; font: 10pt Times New Roman, Times, serif; text-align: left"> <tr> <td style="vertical-align: top; padding-bottom: 2px; vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; vertical-align: bottom"> </td> <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom"> <div style="line-height: 1.25"> <div style="text-align: center; line-height: 1.25; font-weight: bold">In USD and NIS</div> </div> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap; vertical-align: bottom"> </td> </tr> <tr> <td style="vertical-align: top; padding-bottom: 2px; vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; vertical-align: bottom"> </td> <td colspan="2" style="vertical-align: top; border-bottom: #000000 2px solid; vertical-align: bottom"> <div style="line-height: 1.25"> <div style="text-align: center; line-height: 1.25; font-weight: bold">December 31,</div> </div> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap; vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; vertical-align: bottom"> </td> <td colspan="2" style="vertical-align: top; border-bottom: #000000 2px solid; vertical-align: bottom"> <div style="line-height: 1.25"> <div style="text-align: center; line-height: 1.25; font-weight: bold">June 30,</div> </div> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap; vertical-align: bottom"> </td> </tr> <tr> <td style="vertical-align: top; padding-bottom: 2px; vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; vertical-align: bottom"> </td> <td colspan="2" style="vertical-align: top; border-bottom: #000000 2px solid; vertical-align: bottom"> <div style="line-height: 1.25"> <div style="text-align: center; line-height: 1.25; font-weight: bold"> 2018</div> </div> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap; vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; vertical-align: bottom"> </td> <td colspan="2" style="vertical-align: top; border-bottom: #000000 2px solid; vertical-align: bottom"> <div style="line-height: 1.25"> <div style="text-align: center; line-height: 1.25; font-weight: bold">2019</div> </div> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap; vertical-align: bottom"> </td> </tr> <tr> <td style="vertical-align: top; vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; vertical-align: bottom"> </td> <td colspan="2" style="vertical-align: top; vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; vertical-align: bottom"> </td> <td colspan="2" style="vertical-align: top; vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom"> </td> </tr> <tr> <td style="vertical-align: top; width: 76%; padding-bottom: 4px; background-color: rgb(204, 238, 255); vertical-align: bottom"> <div style="line-height: 1.25">Authorized share capital (in NIS)</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: rgb(0, 0, 0) 4px double; background-color: rgb(204, 238, 255); vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: rgb(0, 0, 0) 4px double; background-color: rgb(204, 238, 255); vertical-align: bottom"> <div style="line-height: 1.25"> <div style="line-height: 1.25">25,000,000</div> </div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap; vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: rgb(0, 0, 0) 4px double; background-color: rgb(204, 238, 255); vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: rgb(0, 0, 0) 4px double; background-color: rgb(204, 238, 255); vertical-align: bottom"> <div style="line-height: 1.25"> <div style="line-height: 1.25">25,000,000</div> </div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap; vertical-align: bottom"> </td> </tr> <tr> <td style="vertical-align: top; width: 76%; background-color: rgb(255, 255, 255); vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(255, 255, 255); vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(255, 255, 255); vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(255, 255, 255); vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(255, 255, 255); white-space: nowrap; vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(255, 255, 255); vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(255, 255, 255); vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(255, 255, 255); vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(255, 255, 255); white-space: nowrap; vertical-align: bottom"> </td> </tr> <tr> <td style="vertical-align: top; width: 76%; padding-bottom: 4px; background-color: rgb(204, 238, 255); vertical-align: bottom"> <div style="line-height: 1.25">Issued and paid-up share capital (in NIS)</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: rgb(0, 0, 0) 4px double; background-color: rgb(204, 238, 255); vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: rgb(0, 0, 0) 4px double; background-color: rgb(204, 238, 255); vertical-align: bottom"> <div style="line-height: 1.25"> <div style="line-height: 1.25">11,493,314</div> </div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap; vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: rgb(0, 0, 0) 4px double; background-color: rgb(204, 238, 255); vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: rgb(0, 0, 0) 4px double; background-color: rgb(204, 238, 255); vertical-align: bottom"> <div style="line-height: 1.25"> <div style="line-height: 1.25">14,718,374</div> </div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap; vertical-align: bottom"> </td> </tr> <tr> <td style="vertical-align: top; width: 76%; background-color: rgb(255, 255, 255); vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(255, 255, 255); vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(255, 255, 255); vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(255, 255, 255); vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(255, 255, 255); white-space: nowrap; vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(255, 255, 255); vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(255, 255, 255); vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(255, 255, 255); vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(255, 255, 255); white-space: nowrap; vertical-align: bottom"> </td> </tr> <tr> <td style="vertical-align: top; width: 76%; padding-bottom: 4px; background-color: rgb(204, 238, 255); vertical-align: bottom"> <div style="line-height: 1.25">Issued and paid-up share capital (in USD)</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: rgb(0, 0, 0) 4px double; background-color: rgb(204, 238, 255); vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: rgb(0, 0, 0) 4px double; background-color: rgb(204, 238, 255); vertical-align: bottom"> <div style="line-height: 1.25"> <div style="line-height: 1.25">3,109,746</div> </div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap; vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: rgb(0, 0, 0) 4px double; background-color: rgb(204, 238, 255); vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: rgb(0, 0, 0) 4px double; background-color: rgb(204, 238, 255); vertical-align: bottom"> <div style="line-height: 1.25"> <div style="line-height: 1.25">4,000,676</div></div></td></tr></table></div>

<div><div><div style="line-height: 1.25"><div style="line-height: 1.25"><br style="line-height: 1.25" /> </div> <table id="z83469f45cfea4f96890d537d84380453" border="0" cellpadding="0" cellspacing="0" align="right" style="width: 91%; color: #000000; font: 10pt Times New Roman, Times, serif; text-align: left"> <tr> <td style="vertical-align: bottom; padding-bottom: 2px; vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; vertical-align: bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom"> <div style="line-height: 1.25"> <div style="text-align: center; line-height: 1.25; font-weight: bold">January 1,</div> </div> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap; vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; vertical-align: bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom"> <div style="line-height: 1.25"> <div style="text-align: center; line-height: 1.25; font-weight: bold">June 30,</div> </div> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap; vertical-align: bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; padding-bottom: 2px; vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; vertical-align: bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom"> <div style="line-height: 1.25"> <div style="text-align: center; line-height: 1.25; font-weight: bold"> 2019</div> </div> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap; vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; vertical-align: bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom"> <div style="line-height: 1.25"> <div style="text-align: center; line-height: 1.25; font-weight: bold">2019</div> </div> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap; vertical-align: bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom"> <div style="line-height: 1.25">Composition of right-of-use assets by type:</div> </td> <td colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom"> </td> <td colspan="2" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap; vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom"> </td> <td colspan="2" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap; vertical-align: bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; background-color: rgb(255, 255, 255); vertical-align: bottom"> <div style="text-indent: 14.2pt; line-height: 1.25">Property</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(255, 255, 255); vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(255, 255, 255); vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(255, 255, 255); vertical-align: bottom"> <div style="line-height: 1.25">1,552</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(255, 255, 255); white-space: nowrap; vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(255, 255, 255); vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(255, 255, 255); vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(255, 255, 255); vertical-align: bottom"> <div style="line-height: 1.25">1,485</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(255, 255, 255); white-space: nowrap; vertical-align: bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: rgb(204, 238, 255); vertical-align: bottom"> <div style="text-indent: 14.2pt; line-height: 1.25">Motor vehicles</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: rgb(0, 0, 0) 2px solid; background-color: rgb(204, 238, 255); vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: rgb(0, 0, 0) 2px solid; background-color: rgb(204, 238, 255); vertical-align: bottom"> <div style="line-height: 1.25"> <div style="line-height: 1.25">326</div> </div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap; vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: rgb(0, 0, 0) 2px solid; background-color: rgb(204, 238, 255); vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: rgb(0, 0, 0) 2px solid; background-color: rgb(204, 238, 255); vertical-align: bottom"> <div style="line-height: 1.25"> <div style="line-height: 1.25">231</div> </div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap; vertical-align: bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: rgb(255, 255, 255); vertical-align: bottom"> <div style="text-indent: 28.35pt; line-height: 1.25">Total right-of-use asset</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(255, 255, 255); vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: rgb(0, 0, 0) 2px solid; background-color: rgb(255, 255, 255); vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: rgb(0, 0, 0) 2px solid; background-color: rgb(255, 255, 255); vertical-align: bottom"> <div style="line-height: 1.25"> <div style="line-height: 1.25">1,878</div> </div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(255, 255, 255); white-space: nowrap; vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(255, 255, 255); vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: rgb(0, 0, 0) 2px solid; background-color: rgb(255, 255, 255); vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: rgb(0, 0, 0) 2px solid; background-color: rgb(255, 255, 255); vertical-align: bottom"> <div style="line-height: 1.25"> <div style="line-height: 1.25">1,716</div> </div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(255, 255, 255); white-space: nowrap; vertical-align: bottom"> </td> </tr> </table> <div style="line-height: 1.25; clear: both"><br style="line-height: 1.25" /> </div> <table id="z62bcf0e410bd4ba7a264d5799588b83e" border="0" cellpadding="0" cellspacing="0" align="right" style="width: 91%; color: #000000; font: 10pt Times New Roman, Times, serif; text-align: left"> <tr> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 84%; vertical-align: bottom"> <div style="line-height: 1.25">Composition of lease liabilities recognized as of January 1, 2019:</div> </td> <td colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom"> </td> <td colspan="2" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%; white-space: nowrap; vertical-align: bottom"> </td> <td colspan="1" style="background-color: #FFFFFF; vertical-align: bottom; white-space: nowrap; width: 4%"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 84%; background-color: rgb(255, 255, 255); vertical-align: bottom"> <div style="text-indent: 14.2pt; line-height: 1.25">Current lease liabilities</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(255, 255, 255); vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(255, 255, 255); vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(255, 255, 255); vertical-align: bottom"> <div style="line-height: 1.25">713</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(255, 255, 255); white-space: nowrap; vertical-align: bottom"> </td> <td colspan="1" style="background-color: #FFFFFF; vertical-align: bottom; white-space: nowrap; width: 4%"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 84%; padding-bottom: 2px; background-color: rgb(204, 238, 255); vertical-align: bottom"> <div style="text-indent: 14.2pt; line-height: 1.25">Non-current lease liabilities</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: rgb(0, 0, 0) 2px solid; background-color: rgb(204, 238, 255); vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: rgb(0, 0, 0) 2px solid; background-color: rgb(204, 238, 255); vertical-align: bottom"> <div style="line-height: 1.25"> <div style="line-height: 1.25">1,165</div> </div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap; vertical-align: bottom"> </td> <td colspan="1" style="background-color: #FFFFFF; vertical-align: bottom; white-space: nowrap; width: 4%; padding: 0px 0px 2px"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 84%; padding-bottom: 2px; background-color: rgb(255, 255, 255); vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(255, 255, 255); vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: rgb(0, 0, 0) 2px solid; background-color: rgb(255, 255, 255); vertical-align: bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: rgb(0, 0, 0) 2px solid; background-color: rgb(255, 255, 255); vertical-align: bottom"> <div style="line-height: 1.25"> <div style="line-height: 1.25">1,878</div></div></td></tr></table></div></div></div>

292000 -1000 442000 377000

1000

<div><div><div style="line-height: 1.25"><div style="text-indent: -49.6pt; margin-left: 49.6pt; line-height: 1.25; font-weight: bold">NOTE 4 – ISSUANCES OF SHARE CAPITAL AND WARRANTS</div> <div style="line-height: 1.25"><br style="line-height: 1.25" /> </div> <div style="text-align: justify; line-height: 1.25"> <div> <table class="DSPFListTable" id="z5ec8ca28b9af4744ba64af2c4d426913" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000"> <tr> <td style="width: 51.05pt"><br /> </td> <td style="width: 18pt; vertical-align: top; font-weight: bold">a.</td> <td style="width: auto; vertical-align: top; text-align: justify"> <div style="font-weight: bold">At-the-market (“ATM”) sales agreement with BTIG</div> </td> </tr> </table> </div> </div> <div style="text-align: justify; line-height: 1.25"><br style="line-height: 1.25" /> </div> <div style="text-align: justify; margin-left: 70.9pt; line-height: 1.25">In October 2017, the Company entered into an at-the-market (“ATM”) sales agreement with BTIG, LLC (“BTIG”), pursuant to which the Company may, at its sole discretion, offer and sell through BTIG, acting as sales agent, ADSs having an aggregate offering price of up to $30.0 million throughout the period during which the ATM facility remains in effect. The Company will pay BTIG a commission of 3.0% of the gross proceeds from the sale of ADSs under the facility. From the effective date of the agreement through June 30, 2019, 9,655,387 ADSs were sold under the program for total net proceeds of approximately $7.0 million, leaving an available balance under the facility of approximately $23.0 million as of June 30, 2019.</div> <div style="line-height: 1.25"><br style="line-height: 1.25" /> </div> <div style="text-align: justify; line-height: 1.25"> <div> <table class="DSPFListTable" id="z81571fd8320d4140a9b29b49512d6597" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000"> <tr> <td style="width: 51.05pt"><br /> </td> <td style="width: 18pt; vertical-align: top; font-weight: bold">b.</td> <td style="width: auto; vertical-align: top; text-align: justify"> <div style="font-weight: bold">Underwritten public offering</div> </td> </tr> </table> </div> </div> <div style="line-height: 1.25"><br style="line-height: 1.25" /> </div> <div style="line-height: 1.25"> <div style="text-align: justify; margin-left: 69.05pt; line-height: 1.25">In February 2019, the Company completed an underwritten public offering of 28,000,000 of its ADSs and warrants to purchase 28,000,000 ADSs, at a public offering price of $0.55 per ADS and accompanying warrant. The warrants are exercisable immediately, expire five years from the date of issuance and have an exercise price of $0.75 per ADS. The offering raised a total of $15.4 million, with net proceeds of $14.1 million, after deducting fees and expenses. The amount of the offering consideration initially allocated to the warrants was $5.0 million. Total issuance costs initially allocated to the warrants were $0.4 million.</div> <div style="line-height: 1.25"><br style="line-height: 1.25" /> </div> <div style="text-align: justify; margin-left: 70.9pt; line-height: 1.25">The warrants issued have been classified as a non-current financial liability due to a net settlement provision. This liability was initially recognized at its fair value on the date the contract was entered into and is subsequently accounted for at fair value at each balance sheet date. The fair value changes are charged to non-operating income and expense in the statement of comprehensive loss.</div> <div style="line-height: 1.25"><br style="line-height: 1.25" /> </div> <div style="text-align: justify; margin-left: 70.9pt; line-height: 1.25">The fair value of the warrants is computed using the Black and Scholes option pricing model. The fair value of the warrants upon issuance was computed based on the then current price of an ADS, a risk-free interest rate of 2.50% and an average standard deviation of 62.8%. The fair value of the warrants as of June 30, 2019 was based on the then current price of an ADS, a risk-free interest rate of 1.76% and an average standard deviation of 65.2%. The change in fair value from the date of issuance through June 30, 2019 amounted to $1.3 million.</div></div></div></div></div>

<div><div><div style="line-height: 1.25"><div style="line-height: 1.25; clear: both"></div> <div id="DSPFPageHeader"> <div style="line-height: 1.25; font-weight: bold">NOTE 6 – EVENT SUBSEQUENT TO THE BALANCE SHEET DATE</div> <br /> </div> <div style="line-height: 1.25"> <div style="text-align: justify; margin-left: 49.6pt; line-height: 1.25">On July 15, 2019, the Company implemented a change in the ratio of its ADSs to ordinary shares, from one ADS representing one ordinary share to a new ratio of one ADS representing 15 ordinary shares.</div> </div></div></div></div>

1300000

400000

200000

EX-101.SCH 6 blrx-20190630.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - CONDENSED CONSOLIDATED INTERIM STATEMENTS OF FINANCIAL POSITION (UNAUDITED) link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - CONDENSED CONSOLIDATED INTERIM STATEMENTS OF COMPREHENSIVE LOSS (UNAUDITED) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - CONDENSED INTERIM STATEMENTS OF CHANGES IN EQUITY (UNAUDITED) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - CONDENSED CONSOLIDATED INTERIM CASH FLOW STATEMENTS (UNAUDITED) link:presentationLink link:calculationLink link:definitionLink 00000006 - Disclosure - GENERAL INFORMATION link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - BASIS OF PREPARATION link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - ISSUANCES OF SHARE CAPITAL AND WARRANTS link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - SHAREHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - EVENT SUBSEQUENT TO THE BALANCE SHEET DATE link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - SHAREHOLDERS' EQUITY (Tables) link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Schedule of Composition of Right-of-Use Assets) (Details) link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Schedule of Composition of Lease Liabilities Recognized) (Details) link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - ISSUANCES OF SHARE CAPITAL AND WARRANTS (Details) link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - SHAREHOLDERS' EQUITY (Schedule of Share Capital) (Details) link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - EVENT SUBSEQUENT TO THE BALANCE SHEET DATE (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 blrx-20190630_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 8 blrx-20190630_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 9 blrx-20190630_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Components of equity [axis] Ordinary shares [Member] Share premium [Member] Capital reserve [Member] Accumulated deficit [Member] Foreign Currency [Axis] NIS [Member] Categories of related parties [Axis] BTIG, LLC [Member] ADS [Member] Other comprehensive loss [Member] Public offering [Member] Classes of property, plant and equipment [Axis] Motor vehicles [member] Property [member] Types of share-based payment arrangements [axis] Warrant [Member] Document And Entity Information Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Amendment Flag Current Fiscal Year End Date Entity Filer Category Document Fiscal Period Focus Document Fiscal Year Focus Entity Emerging Growth Company Entity Shell Company Entity Common Stock, Shares Outstanding Statement of financial position [abstract] Assets CURRENT ASSETS Cash and cash equivalents Short-term bank deposits Prepaid expenses Other receivables Total current assets NON-CURRENT ASSETS Long-term prepaid expenses Property and equipment, net Right-of-use assets Intangible assets, net Total non-current assets Total assets Liabilities and equity CURRENT LIABILITIES Current maturities of long-term loans Accounts payable and accruals: Trade Other Lease liabilities Total current liabilities NON-CURRENT LIABILITIES Warrants Long-term loans, net of current maturities Lease liabilities Total non-current liabilities COMMITMENTS AND CONTINGENT LIABILITIES Total liabilities EQUITY Ordinary shares Share premium Capital reserve Other comprehensive loss Accumulated deficit Total equity Total liabilities and equity Profit or loss [abstract] RESEARCH AND DEVELOPMENT EXPENSES SALES AND MARKETING EXPENSES GENERAL AND ADMINISTRATIVE EXPENSES OPERATING LOSS NON-OPERATING INCOME, NET FINANCIAL INCOME FINANCIAL EXPENSES NET LOSS AND COMPREHENSIVE LOSS LOSS PER ORDINARY SHARE - BASIC AND DILUTED WEIGHTED AVERAGE NUMBER OF SHARES USED IN CALCULATION OF LOSS PER ORDINARY SHARE Statement of changes in equity [table] Statement of changes in equity [line items] BALANCE CHANGES FOR Issuance of share capital, net Employee stock options exercised Employee stock options forfeited and expired Share-based compensation Other comprehensive loss Comprehensive loss for the period BALANCE Statement of cash flows [abstract] CASH FLOWS - OPERATING ACTIVITIES Adjustments required to reflect net cash used in operating activities (see appendix below) Net cash used in operating activities CASH FLOWS - INVESTING ACTIVITIES Investments in short-term deposits Maturities of short-term deposits Proceeds from realization of long-term investment Purchase of property and equipment Purchase of intangible assets Net cash provided by (used in) investing activities CASH FLOWS - FINANCING ACTIVITIES Issuances of share capital and warrants, net of issuance cost Employee stock options exercised Repayments of loans Repayments of lease liabilities Net cash provided by financing activities INCREASE IN CASH AND CASH EQUIVALENTS CASH AND CASH EQUIVALENTS - BEGINNING OF PERIOD EXCHANGE DIFFERENCES ON CASH AND CASH EQUIVALENTS CASH AND CASH EQUIVALENTS - END OF PERIOD Adjustments required to reflect net cash used in operating activities: Income and expenses not involving cash flows: Depreciation and amortization Long-term prepaid expenses Exchange differences on cash and cash equivalents Gain on adjustment of warrants to fair value Gain on realization of long-term investment Share-based compensation Warrant issuance costs Interest and exchange rate differences on short-term deposits Interest on loans Total income and expense not involving cash flows Changes in operating asset and liability items: Decrease (increase) in prepaid expenses and other receivables Decrease in accounts payable and accruals Total Change in operating asset and liability Total Adjustments required to reflect net cash used in operating acivities Supplemental information on interest received in cash Supplemental information on interest paid in cash Supplemental information on non-cash transaction: Initial establishment of right-of-use assets against lease liabilities Disclosure of general information [Abstract] GENERAL INFORMATION Disclosure of basis of preparation [Abstract] BASIS OF PREPARATION Disclosure of significant accounting policies [Abstract] SIGNIFICANT ACCOUNTING POLICIES Disclosure of issuances of share capital and warrants [Abstract] ISSUANCES OF SHARE CAPITAL AND WARRANTS Disclosure of classes of share capital [abstract] SHAREHOLDERS' EQUITY Disclosure of non-adjusting events after reporting period [abstract] EVENT SUBSEQUENT TO THE BALANCE SHEET DATE Schedule of Composition of Right-of-Use Assets Schedule of Composition of Lease Liabilities Recognized Schedule of Share Capital Schedule of Amounts Outstanding Under Employee Share Incentive Plan Schedule of Options Outstanding by Exercise Price Range Schedule of Assumptions Used to Value Options Disclosure of detailed information about property, plant and equipment [table] Disclosure of detailed information about property, plant and equipment [line items] Classes of property, plant and equipment [axis] Weighted average incremental borrowing rate of lease liabilities Weighted Average Remaining Lease Term Lease expense Cash paid for amounts included in the measurement of the operating lease liabilities Property Motor vehicles Total right-of-use asset Current lease liabilities Non-current lease liabilities Total Lease Liabilities Disclosure of terms and conditions of share-based payment arrangement [table] Disclosure of terms and conditions of share-based payment arrangement [line items] Categories of related parties [axis] Aggregate offering price Percentage of commission on sales agreement Share purchase agreement, shares Available balance under the facility Number of shares issued Number of warrant purchase Offering price per ADS Expiry Exercise of price per ADS Proceeds from shares issued Net proceeds from shares issued after deducting fees and expenses Risk-free interest rate Average standard deviation Issuance costs Change in fair value of issuance Currency [Axis] Number of Ordinary Shares Authorized share capital Issued and paid-up share capital Authorized share capital Issued and paid-up share capital Disclosure of non-adjusting events after reporting period [table] Disclosure of non-adjusting events after reporting period [line items] Non-adjusting events after reporting period [axis] Nonadjusting Event [Member] ADSs to ordinary shares ratio Adjustments for decrease (increase) in prepaid expense other operating receivables to reconcile profit (loss) to net cash flow from (used in) operating activities. Agalimmune Ltd [Member] Aggregate offering price. ADS [Member] American stock exchange [Member] Amount of authorized share capital. Available balance under the facility Available balance under the facility EX-101.PRE 10 blrx-20190630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 11 image0.jpg begin 644 image0.jpg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end XML 12 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information	6 Months Ended
Document and Entity Information	Jun. 30, 2019
Document And Entity Information
Entity Registrant Name	BioLineRx Ltd.
Entity Central Index Key	0001498403
Document Type	6-K
Document Period End Date	Jun. 30, 2019
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2019

XML 13 R2.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED INTERIM STATEMENTS OF FINANCIAL POSITION (UNAUDITED) - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
CURRENT ASSETS
Cash and cash equivalents	$ 4,972	$ 3,404
Short-term bank deposits	30,256	26,747
Prepaid expenses	451	488
Other receivables	528	1,339
Total current assets	36,207	31,978
NON-CURRENT ASSETS
Long-term prepaid expenses	60	56
Property and equipment, net	2,047	2,227
Right-of-use assets	1,716
Intangible assets, net	21,928	21,972
Total non-current assets	25,751	24,255
Total assets	61,958	56,233
CURRENT LIABILITIES
Current maturities of long-term loans	2,395	895
Accounts payable and accruals:
Trade	4,565	4,493
Other	927	1,363
Lease liabilities	672
Total current liabilities	8,559	6,751
NON-CURRENT LIABILITIES
Warrants	3,938	323
Long-term loans, net of current maturities	6,583	7,838
Lease liabilities	1,096
Total non-current liabilities	11,617	8,161
COMMITMENTS AND CONTINGENT LIABILITIES
Total liabilities	20,176	14,912
EQUITY
Ordinary shares	4,001	3,110
Share premium	261,522	250,192
Capital reserve	11,835	11,955
Other comprehensive loss	(1,416)	(1,416)
Accumulated deficit	(234,160)	(222,520)
Total equity	41,782	41,321
Total liabilities and equity	$ 61,958	$ 56,233

XML 14 R3.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED INTERIM STATEMENTS OF COMPREHENSIVE LOSS (UNAUDITED) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Profit or loss [abstract]
RESEARCH AND DEVELOPMENT EXPENSES	$ (5,302)	$ (4,484)	$ (9,694)	$ (9,554)
SALES AND MARKETING EXPENSES	(226)	(360)	(482)	(844)
GENERAL AND ADMINISTRATIVE EXPENSES	(949)	(883)	(1,879)	(1,958)
OPERATING LOSS	(6,477)	(5,727)	(12,055)	(12,356)
NON-OPERATING INCOME, NET	1,261	663	921	1,125
FINANCIAL INCOME	171	287	381	462
FINANCIAL EXPENSES	(440)	(11)	(887)	(217)
NET LOSS AND COMPREHENSIVE LOSS	$ (5,485)	$ (4,788)	$ (11,640)	$ (10,986)
LOSS PER ORDINARY SHARE - BASIC AND DILUTED	$ (0.04)	$ (0.05)	$ (0.08)	$ (0.1)
WEIGHTED AVERAGE NUMBER OF SHARES USED IN CALCULATION OF LOSS PER ORDINARY SHARE	145,461,598	106,630,704	139,270,178	106,524,332

XML 15 R4.htm IDEA: XBRL DOCUMENT

CONDENSED INTERIM STATEMENTS OF CHANGES IN EQUITY (UNAUDITED) - USD ($) $ in Thousands	Ordinary shares [Member]	Share premium [Member]	Capital reserve [Member]	Other comprehensive loss [Member]	Accumulated deficit [Member]	Total
BALANCE at Dec. 31, 2017	$ 2,836	$ 240,682	$ 10,337	$ (1,416)	$ (199,558)	$ 52,881
CHANGES FOR
Issuance of share capital, net	83	2,764				2,847
Employee stock options exercised	1	38	(39)
Employee stock options forfeited and expired		399	(399)
Share-based compensation			1,444			1,444
Comprehensive loss for the period					(10,986)	(10,986)
BALANCE at Jun. 30, 2018	2,920	243,883	11,343	(1,416)	(210,544)	46,186
BALANCE at Dec. 31, 2018	3,110	250,192	11,955	(1,416)	(222,520)	41,321
CHANGES FOR
Issuance of share capital, net	890	10,437				11,327
Employee stock options exercised	1	27	(27)			1
Employee stock options forfeited and expired		866	(866)
Share-based compensation			773			773
Comprehensive loss for the period					(11,640)	(11,640)
BALANCE at Jun. 30, 2019	$ 4,001	$ 261,522	$ 11,835	$ (1,416)	$ (234,160)	$ 41,782

- Definition

The amount of residual interest in the assets of the entity after deducting all its liabilities.

+ References + Details

- Definition

The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 7
-IssueDate 2018-01-01
-Paragraph 18
-Subparagraph b
-URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&num=7&date=2018-03-01&anchor=para_18_b&doctype=Standard
-URIDate 2018-03-16

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 1
-IssueDate 2018-01-01
-Paragraph 24
-Subparagraph b
-URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&num=1&date=2018-03-01&anchor=para_24_b&doctype=Standard
-URIDate 2018-03-16

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 1
-IssueDate 2018-01-01
-Paragraph 32
-Subparagraph a
-Clause ii
-URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&num=1&date=2018-03-01&anchor=para_32_a_ii&doctype=Standard
-URIDate 2018-03-16

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 8
-IssueDate 2018-01-01
-Paragraph 28
-Subparagraph b
-URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&num=8&date=2018-03-01&anchor=para_28_b&doctype=Standard
-URIDate 2018-03-16

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Note Effective on first application of IFRS 9
-Name IFRS
-Number 4
-IssueDate 2018-01-01
-Paragraph 39L
-Subparagraph e
-URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&num=4&date=2018-03-02&anchor=para_39L_e&doctype=Standard&book=b
-URIDate 2018-03-16

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 8
-IssueDate 2018-01-01
-Paragraph 23
-URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&num=8&date=2018-03-01&anchor=para_23&doctype=Standard
-URIDate 2018-03-16

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Name IFRS
-Number 12
-IssueDate 2018-01-01
-Paragraph B10
-Subparagraph b
-URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&num=12&date=2018-03-01&anchor=para_B10_b&doctype=Appendix&seq=2
-URIDate 2018-03-16

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 1
-IssueDate 2018-01-01
-Paragraph 106
-Subparagraph d
-Clause i
-URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&num=1&date=2018-03-01&anchor=para_106_d_i&doctype=Standard
-URIDate 2018-03-16

Reference 9: http://www.xbrl.org/2003/role/exampleRef
-Note Effective 2021-01-01
-Name IFRS
-Number 17
-IssueDate 2018-01-01
-Paragraph 113
-Subparagraph b
-URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&num=17&date=2018-03-01&anchor=para_113_b&doctype=Standard
-URIDate 2018-03-16

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 1
-IssueDate 2018-01-01
-Paragraph 81A
-Subparagraph a
-URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&num=1&date=2018-03-01&anchor=para_81A_a&doctype=Standard
-URIDate 2018-03-16

+ Details

XML 16 R5.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED INTERIM CASH FLOW STATEMENTS (UNAUDITED) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
CASH FLOWS - OPERATING ACTIVITIES
Comprehensive loss for the period	$ (11,640)	$ (10,986)
Adjustments required to reflect net cash used in operating activities (see appendix below)	573	(2,054)
Net cash used in operating activities	(11,067)	(13,040)
CASH FLOWS - INVESTING ACTIVITIES
Investments in short-term deposits	(27,510)	(15,000)
Maturities of short-term deposits	24,441	24,385
Proceeds from realization of long-term investment		1,500
Purchase of property and equipment	(53)	(76)
Purchase of intangible assets		(37)
Net cash provided by (used in) investing activities	(3,122)	10,772
CASH FLOWS - FINANCING ACTIVITIES
Issuances of share capital and warrants, net of issuance cost	15,879	2,847
Employee stock options exercised	1
Repayments of loans	(47)	(47)
Repayments of lease liabilities	(110)
Net cash provided by financing activities	15,723	2,800
INCREASE IN CASH AND CASH EQUIVALENTS	1,534	532
CASH AND CASH EQUIVALENTS - BEGINNING OF PERIOD	3,404	5,110
EXCHANGE DIFFERENCES ON CASH AND CASH EQUIVALENTS	34	147
CASH AND CASH EQUIVALENTS - END OF PERIOD	4,972	5,789
Income and expenses not involving cash flows:
Depreciation and amortization	439	288
Long-term prepaid expenses	(4)	(2)
Exchange differences on cash and cash equivalents	(34)	(147)
Gain on adjustment of warrants to fair value	(1,354)	(625)
Gain on realization of long-term investment		(500)
Share-based compensation	773	1,444
Warrant issuance costs	417
Interest and exchange rate differences on short-term deposits	(440)	(351)
Interest on loans	292	(1)
Total income and expense not involving cash flows	89	106
Changes in operating asset and liability items:
Decrease (increase) in prepaid expenses and other receivables	848	(776)
Decrease in accounts payable and accruals	(364)	(1,384)
Total Change in operating asset and liability	484	(2,160)
Total Adjustments required to reflect net cash used in operating acivities	573	(2,054)
Supplemental information on interest received in cash	442	377
Supplemental information on interest paid in cash	477	167
Supplemental information on non-cash transaction:
Initial establishment of right-of-use assets against lease liabilities	$ 1,878

XML 17 R6.htm IDEA: XBRL DOCUMENT

GENERAL INFORMATION

6 Months Ended

Jun. 30, 2019

Disclosure of general information [Abstract]

GENERAL INFORMATION

NOTE 1 – GENERAL INFORMATION

General

BioLineRx Ltd. (“BioLineRx”), headquartered in Modi’in, Israel, was incorporated and commenced operations in April 2003.

BioLineRx and its subsidiaries (collectively, the “Company”) are engaged in the development of therapeutics, primarily in clinical-stages, with a focus on the field of oncology.

In March 2017, the Company acquired Agalimmune Ltd. (“Agalimmune”), a privately-held company incorporated in the United Kingdom, with a focus on the field of immuno-oncology.

Approval of financial statements

XML 18 R7.htm IDEA: XBRL DOCUMENT

BASIS OF PREPARATION	6 Months Ended
BASIS OF PREPARATION	Jun. 30, 2019
Disclosure of basis of preparation [Abstract]
BASIS OF PREPARATION	NOTE 2 – BASIS OF PREPARATION The Company’s condensed consolidated interim financial statements as of June 30, 2019 and for the three and six months then ended (the “interim financial statements”) have been prepared in accordance with International Accounting Standard No. 34, “Interim Financial Reporting” (“IAS 34”). These interim financial statements, which are unaudited, do not include all disclosures necessary for a fair statement of financial position, results of operations, and cash flows in conformity with International Financial Reporting Standards (“IFRS”). The condensed consolidated interim financial statements should be read in conjunction with the Company’s annual financial statements as of December 31, 2018 and for the year then ended and their accompanying notes, which have been prepared in accordance with IFRS. The results of operations for the three and six months ended June 30, 2019 are not necessarily indicative of the results that may be expected for the entire fiscal year or for any other interim period.

XML 19 R8.htm IDEA: XBRL DOCUMENT

SIGNIFICANT ACCOUNTING POLICIES

6 Months Ended

Jun. 30, 2019

Disclosure of significant accounting policies [Abstract]

SIGNIFICANT ACCOUNTING POLICIES

NOTE 3 – SIGNIFICANT ACCOUNTING POLICIES

Adjustments recognized on adoption of IFRS 16

	January 1,		June 30,
	2019		2019
Composition of right-of-use assets by type:
Property		1,552		1,485
Motor vehicles		326		231
Total right-of-use asset		1,878		1,716

Composition of lease liabilities recognized as of January 1, 2019:
Current lease liabilities			713
Non-current lease liabilities			1,165
			1,878

Practical expedients applied on adoption of IFRS 16

In applying IFRS 16 for the first time, the Company has used the following practical expedients permitted by the standard:

•

Use of a single discount rate to a portfolio of leases with reasonably similar characteristics;

•

Reliance on previous assessments on whether leases are onerous;

•

Accounting for operating leases with a remaining lease term of less than 12 months as of January 1, 2019, as short-term leases;

•

Exclusion of initial direct costs for the measurement of the right-of-use asset at the date of initial application;

•

Use of hindsight in determining the lease term where the contract contains options to extend or terminate the lease.

Other information relating to IFRS 16

XML 20 R9.htm IDEA: XBRL DOCUMENT

ISSUANCES OF SHARE CAPITAL AND WARRANTS

6 Months Ended

Jun. 30, 2019

Disclosure of issuances of share capital and warrants [Abstract]

ISSUANCES OF SHARE CAPITAL AND WARRANTS

NOTE 4 – ISSUANCES OF SHARE CAPITAL AND WARRANTS

At-the-market (“ATM”) sales agreement with BTIG

Underwritten public offering

XML 21 R10.htm IDEA: XBRL DOCUMENT

SHAREHOLDERS' EQUITY

6 Months Ended

Jun. 30, 2019

Disclosure of classes of share capital [abstract]

SHAREHOLDERS' EQUITY

NOTE 5 – SHAREHOLDERS’ EQUITY

As of December 31, 2018 and June 30, 2019, share capital is composed of ordinary shares, as follows:

	Number of ordinary shares
	December 31,		June 30,
	2018		2019

Authorized share capital		250,000,000		250,000,000

Issued and paid-up share capital		114,933,144		147,183,744

	In USD and NIS
	December 31,		June 30,
	2018		2019

Authorized share capital (in NIS)		25,000,000		25,000,000

Issued and paid-up share capital (in NIS)		11,493,314		14,718,374

Issued and paid-up share capital (in USD)		3,109,746		4,000,676

XML 22 R11.htm IDEA: XBRL DOCUMENT

EVENT SUBSEQUENT TO THE BALANCE SHEET DATE	6 Months Ended
EVENT SUBSEQUENT TO THE BALANCE SHEET DATE	Jun. 30, 2019
Disclosure of non-adjusting events after reporting period [abstract]
EVENT SUBSEQUENT TO THE BALANCE SHEET DATE	NOTE 6 – EVENT SUBSEQUENT TO THE BALANCE SHEET DATE On July 15, 2019, the Company implemented a change in the ratio of its ADSs to ordinary shares, from one ADS representing one ordinary share to a new ratio of one ADS representing 15 ordinary shares.

XML 23 R12.htm IDEA: XBRL DOCUMENT

SIGNIFICANT ACCOUNTING POLICIES (Tables)

6 Months Ended

Jun. 30, 2019

Disclosure of significant accounting policies [Abstract]

Schedule of Composition of Right-of-Use Assets

	January 1,		June 30,
	2019		2019
Composition of right-of-use assets by type:
Property		1,552		1,485
Motor vehicles		326		231
Total right-of-use asset		1,878		1,716

Composition of lease liabilities recognized as of January 1, 2019:
Current lease liabilities			713
Non-current lease liabilities			1,165
			1,878

XML 24 R13.htm IDEA: XBRL DOCUMENT

SHAREHOLDERS' EQUITY (Tables)

6 Months Ended

Jun. 30, 2019

Disclosure of classes of share capital [abstract]

Schedule of Share Capital

As of December 31, 2018 and June 30, 2019, share capital is composed of ordinary shares, as follows:

	Number of ordinary shares
	December 31,		June 30,
	2018		2019

Authorized share capital		250,000,000		250,000,000

Issued and paid-up share capital		114,933,144		147,183,744

	In USD and NIS
	December 31,		June 30,
	2018		2019

Authorized share capital (in NIS)		25,000,000		25,000,000

Issued and paid-up share capital (in NIS)		11,493,314		14,718,374

Issued and paid-up share capital (in USD)		3,109,746		4,000,676

XML 25 R14.htm IDEA: XBRL DOCUMENT

SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2019	Jan. 02, 2019
Disclosure of detailed information about property, plant and equipment [line items]
Weighted average incremental borrowing rate of lease liabilities		15.10%
Lease expense	$ 200
Cash paid for amounts included in the measurement of the operating lease liabilities	$ 100
Property [member]
Disclosure of detailed information about property, plant and equipment [line items]
Weighted Average Remaining Lease Term	11 years
Motor vehicles [member]
Disclosure of detailed information about property, plant and equipment [line items]
Weighted Average Remaining Lease Term	1 year 2 months 12 days

XML 26 R15.htm IDEA: XBRL DOCUMENT

SIGNIFICANT ACCOUNTING POLICIES (Schedule of Composition of Right-of-Use Assets) (Details) - USD ($) $ in Thousands	Jun. 30, 2019	Jan. 02, 2019
Disclosure of significant accounting policies [Abstract]
Property	$ 1,485	$ 1,552
Motor vehicles	231	326
Total right-of-use asset	$ 1,716	$ 1,878

XML 27 R16.htm IDEA: XBRL DOCUMENT

SIGNIFICANT ACCOUNTING POLICIES (Schedule of Composition of Lease Liabilities Recognized) (Details) - USD ($) $ in Thousands	Jun. 30, 2019	Jan. 02, 2019
Disclosure of significant accounting policies [Abstract]
Current lease liabilities	$ 672	$ 713
Non-current lease liabilities	$ 1,096	1,165
Total Lease Liabilities		$ 1,878

XML 28 R17.htm IDEA: XBRL DOCUMENT

ISSUANCES OF SHARE CAPITAL AND WARRANTS (Details) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended	6 Months Ended
	Feb. 28, 2019	Jun. 30, 2019	Jun. 30, 2018	Oct. 31, 2017
Disclosure of terms and conditions of share-based payment arrangement [line items]
Proceeds from shares issued		$ 15,879	$ 2,847
Change in fair value of issuance		$ 1,300
ADS [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Risk-free interest rate	2.50%	1.76%
Average standard deviation	62.80%	65.20%
BTIG, LLC [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Aggregate offering price				$ 30,000
Percentage of commission on sales agreement				3.00%
Share purchase agreement, shares		9,655,387
Available balance under the facility		$ 23,000
Proceeds from shares issued		$ 7,000
Public offering [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of shares issued	28,000,000
Number of warrant purchase	28,000,000
Offering price per ADS	$ 0.55
Expiry	Five years
Exercise of price per ADS	$ 0.75
Proceeds from shares issued	$ 15,400
Net proceeds from shares issued after deducting fees and expenses	14,100
Public offering [Member] \| Warrant [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Proceeds from shares issued	5,000
Issuance costs	$ 400

XML 29 R18.htm IDEA: XBRL DOCUMENT

SHAREHOLDERS' EQUITY (Schedule of Share Capital) (Details) ₪ in Thousands, $ in Thousands	Jun. 30, 2019 USD ($) shares	Jun. 30, 2019 ILS (₪) shares	Dec. 31, 2018 USD ($) shares	Dec. 31, 2018 ILS (₪) shares
Number of Ordinary Shares
Authorized share capital \| shares	250,000,000	250,000,000	250,000,000	250,000,000
Issued and paid-up share capital \| shares	147,183,744	147,183,744	114,933,144	114,933,144
Issued and paid-up share capital \| $	$ 4,000,676		$ 3,109,746
NIS [Member]
Number of Ordinary Shares
Authorized share capital \| ₪		₪ 25,000,000		₪ 25,000,000
Issued and paid-up share capital \| ₪		₪ 14,718,374		₪ 11,493,314

EXCEL 30 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( &HY!D\?(\\#P !," + 7W)E;',O+G)E;'.MDD^+ MPD ,Q;]*F?L:5\'#8CUYZ6U9_ )Q)OU#.Y,A$[%^>X>];+=44/ 87O+>CT?V M/S2@=AQ2V\54C'X(J32M:OP"2+8ECVG%D4)6:A:/FD=I(*+ML2'8K-<[D*F' M.>RGGD7E2B.5^S3%":4A+,*P).B0\5?UX^8 TBTH_0(:+L A#&^NQT:E8(C M-R."?S]PN -02P,$% @ :CD&3R?HAPZ" L0 ! !D;V-0&UL38Y-"\(P$$3_2NG=;BGH06) L$?!D_>0;FP@R8;-"OGYIH(? MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/ M-(X'P"J8%EQV^3O8:W7..7AKQ%/25V^9"CGIYFHQ*/B76_..7+8\#?NW_+"" MWTG] E!+ P04 " !J.09/*W-)_.\ K @ $0 &1O8U!R;W!S+V-O M&ULS9+!2@,Q$(9?17+?G:3%JF&;B^))0;"@> O)M W=[(9D9+=O;S:V M6T0?P&-F_GSS#4QC@C1]Q)?8!XSD,%V-ONV2-&'-]D1! B2S1Z]3G1-=;F[[ MZ#7E9]Q!T.:@=P@+SE?@D;35I&$"5F$F,M58(TU$37T\X:V9\>$SM@5F#6"+ M'CM*(&H!3$T3PW%L&[@ )AAA].F[@'8FENJ?V-(!=DJ.R0%W$?:]=5OWCXW/@JJ!7W>AO@!02P,$% @ :CD&3YE&UL[5I;<]HX%'[OK]!X9_9M"\8V@;:T M$W-I=MNTF83M3A^%$5B-;'EDD81_OTV23;J;/ 0LZ?O.14?GZ#AY M\^XN8NB&B)3R> +]O6N[!3+UES@6QHO(];JM-O=5H1I;*$81V1@?5XL:$#05%%:;U\@M.4? M,_@5RU2-9:,!$U=!)KF(M/+Y;,7\VMX^9<_I.ATR@6XP&U@@?\YOI^1.6HCA M5,+$P&IG/U9KQ]'22(""R7V4!;I)]J/3%0@R#3LZG5C.=GSVQ.V?C,K:=#1M M&N#C\7@XMLO2BW A(5M>5 TR 6'!VULS2 Y9>*?IUE!K9';O=05SP6.XYB1'^QL4$UFG2&98T M1G*=D 4. #?$T4Q0?*]!MHK@PI+27)#6SRFU4!H(FLB!]4>"(<7K;YH]5Z%82=J$^!!&&N*<<^9ST6S[!Z5&T?95O-RCEU@5 9<8WS2J M-2S%UGB5P/&MG#P=$Q+-E L&08:7)"82J3E^34@3_BNEVOZKR2. MFJW"$2M"/F(9-AIRM1:!MG&IA&!:$L;1>$[2M!'\6:PUDSY@R.S-D77.UI$. M$9)>-T(^8LZ+D!&_'H8X2IKMHG%8!/V>7L-)P>B"RV;]N'Z&U3-L+([W1]07 M2N0/)J<_Z3(T!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL! M_]':-\*K^(+ .7\N?<^E[[GT/:'2MSAD M6R4)RU3393>*$IY"&V[I4_5*E=?EK[DHN#Q;Y.FOH70^+,_Y/%_GM,T+,T.W MF)&Y"M-2D&_#^>G%>!KB.=D$N7V85VWGV-'1^^?!4;"C[SR6'<>( M\J(A[J&&F,_#0X=Y>U^89Y7&4#04;6RL)"Q&MV"XU_$L%.!D8"V@!X.O40+R M4E5@,5O& RN0HGQ,C$7H<.>77%_CT9+CVZ9EM6ZO*7<9;2)2.<)IF!-GJ\K> M9;'!51W/55ORL+YJ/;053L_^6:W(GPP13A8+$DACE!>F2J+S&5.^YRM)Q%4X MOT4SMA*7&+SCYL=Q3E.X$G:V#P(RN;LYJ7IE,6>F\M\M# DL6XA9$N)-7>W5 MYYN MTB42%(JP# 4A%W+C[^^3:G>,U_HL@6V$5#)DU1?*0XG!/3-R0]A4)?.NVB8+ MA=OB5,V[&KXF8$O#>FZ=+2?_VU[4/;07/4;SHYG@'K.'YA,L0Z1^P7V*BH 1JV*^NJ]/^26<.[1[\8$@F_S6VZ3VW> , M?-2K6J5D*Q$_2P=\'Y(&8XQ;]#1?CQ1BK::QK<;:,0QY@%CS#*%F.-^'19H: M,]6+K#F-"F]!U4#E/]O4#6CV#30,9FV-J/D3@H\W/[O#;#"Q([A[8N_ M 5!+ P04 " !J.09/U%+]C1(" ""!@ & 'AL+W=OUS##Y _^RM7*[1X*5L*G6A9YW&H,O\Y/%]"0S"(7RV,8C7W M="HWQM[TXFN9^8&." @44KO :KC#"Q"B/:DX_LQ._453$]?S#^^?3?(JF1L6 M\,+([[:43>8??:^$"@]$OK+Q"\P)[7UOSOX;W($HN(Y$:12,"//UBD%(1FQ[!RFZ:S.^.+#3U> MT6,W?>>D[PQ]MZ+O-NG9B+U;8.\4V%OT9"-@(PYN@<0ID%CTXT; 1IS< @>G MP,&BA]LKX( \N -'I\31YD<;"0?D0:%/3HF3S=]6V@%Y4.HP<+^5P/:PK;8+ M\Z#>X8,7&=H>MB5W8;9%1ZL60('7IOD)KV!#9SKORKHTV&?3<]!_^-2=OV-> MMYWP;DRJ1F3:1<68!!5*\*3N=Z-^",N"0"7U]*#F?.J*TT*R?N[X:/GMY/\ M4$L#!!0 ( &HY!D_\!M%+-00 )84 8 >&PO=V]R:W-H965T&ULA9AACZ-&#(;_2L3W.[ ] \PJB=2DJEJIE5977?N932:;Z""D MP&ZN_[Y V(C8GNN7#;"O/:\G,T_,+*]U\ZT]>M\MOE?EN5U%QZZ[/,5QNSOZ MJF@_UQ=_[O]SJ)NJZ/K;YC5N+XTO]F-05<:8)&E<%:=SM%Z.SYZ;];)^Z\K3 MV3\WB_:MJHKFWXTOZ^LJ@NCCP9?3Z[$;'L3KY:5X]7_Z[NOEN>GOXGN6_:GR MY_94GQ>-/ZRBG^!I2^D0,"K^.OEK.[M>#*6\U/6WX>:W_2I*!D>^]+MN2%'T M'^]^Z\MRR-3[^&=*&MW'' +GUQ_9?QF+[XMY*5J_KFM5,7WV^?I/'Y> MI_P?87H 3@%X#P#SPP": H@%Q#=G8ZD_%UVQ7C;U=='*)^,G?# MPW'NQO_UU;;]T_ MU'@:X\T\GE@1-XD=)>=18ES&ZY B,HG1G1C5B9%.#'-RDZ3S01*T*;,B59AF M)M.]6-6+E5XL\V+%*,8"IDMP:)X[]N M2J;@LM-9AY)UAC=UJ'1LD +?D(HL[V4!.SKM4+9VO,'8*!H2^_&'FD-R@J D@" M;G3>D>0=[T\V)$F&*5@4KWN*SB9] Q9PI#./9*-G.8%)=G .>]WMJK,A1HK M"KP,2X):\38LV?@)C.B"_U?VZ$>'*$F(6DYTDGC\A-2/Q%]85"&BQ= JTE%* M$H"6@YV4%U_(&PO=V]R:W-H M965T&ULC9==;YLP%$#_"N)]Q38VF"B)5$BF3=JD:M.V9YHX M"2K@#)RF^_JK)N%_[!F.,L"-K- M055Y>Z>/JK;_['13Y<9>-ON@/38JW_9!51DP0J*@RHO:7\[[MH=F.=FB\]E15>?,G5:4^+WSJOS9\*_8'TS4$R_DQWZOOROPX/C3V*KADV1:5JMM" MUUZC=@O_GL[6-.P">N)GH<[MY-SK5!ZU?NHN/F\7/NEZI$JU,5V*W!Z>5:;* MLLMD^_%[3.I?:G:!T_/7[!][>2OSF+IM3:W0U9K%=J?*7X5C4_?$\YG\-PP/8&, N M ;;V>P'A&!"^!?!W _@8P/^W@A@#!*@0#.[]8*YRDR_GC3Y[S? \'//NL:,S M86_7IFOL[T[_GQW/UK8^+T4\#YZ[/".2#@B;(O(:6;D(O1"!K7_I!,,ZD3(G MG%T7R%Q")* /_TRR?C?)53=#=*S"/CZ@K$>$-$C=8]\ M$"&!HX%0G$L.!@2ADB@!U!JCA."XET"]A.L%>IP.2#2MPE@$M! HG(SP8(5 M7,([C4"2WW"*4*?(=0J!4^0623AX*C,$DA)D6B$0E3%(M<:H9#(5KZQBU"IV MK<#SD,9NE8C'X)V0(92(&:!6"$49$0*(H5@H(MQ,HF;2-0-E4NF4H0Q.P,R% M(GCC5RZ3,)!GC12C3.!&"6J4N$9@PJ2)6R2&0B[#)+Q/+A-**.0R?#++KWPH MP9<:XAHY:PU!IC<'[X ,HRCH\ J#)%1?8Q2C\0VQ&VLH=<4D%*/(FYU+ MOKWK-LY@O:4SC**M*^Z3X-^I_F6 M?OBN^)HW^Z)NO4=M['ZUWU7NM#;*&I [^PP>[*?,Y:)4.].=QO:\&?;SPX71 MQ_%;);A\,"W_ E!+ P04 " !J.09/E_%E2@@$ "#% & 'AL+W=O MVUKB>_\NQ8S:U] M79^>;+O:['6>5I^*DSZ:7W9%F:>U.2U?[>I4ZG3;!N69+1S'L_/T<+06L_;: M<[F8%6]U=CCJYW)2O>5Y6OZ_U%EQGEM@?5SX?GC=U\T%>S$[I:_Z;UW_@S]7-\:09RDM1_&A.OF[GEM-T MI#.]J9L4J?EZURN=94TFT\?/+JEUK=D$WAY_9(_;P9O!O*257A79?X=MO9]; M@379ZEWZEM7?B_,7W0W(M2;=Z/_2[SHS>-.)J;$ILJK]G&S>JKK(NRRFE3S] M=?D^'-OO]-G@Y97A!QBX@^LF(0V4,7&*Z)RX""5+XAWTV6 )M6*(L+W MT+2*:"F);L)Z&(F'D83I)E!WYI[+JN)25?#3Z)(BB%A10J()$%%D*D.D">V% M:#*,) ^1GB(>JXA'%4$EEA3!7:P\*DF(QAM19DJ@]7"M>!A)'B(]47Q6%)^* M@IZ,)46(*,-(Y-/)IA1>MH?SQ,-(,E"JITK JA)055"K2XH058:1:!A9#R-Q M0.<;.&& M[-!K*=,R"H34F70QKH,Z=H5"K0BKQA(R0#/O8AB %(A:DTI;DMC M* &.BR=A0CGEP3V5C%-BO9!#=4+]+#NFMY0 8*$82K@.A'@F,1R V;"Q,:(8 MIQ6'"2%<(XRV , [+:!6BYB CNFY@)#(32%P%#91$5./ M/+@CF'@$DW M&8GON '@31;(83_0,8\, 8,(H@UEIAA:,_U0<8:9Y&'/?6%X M]PB,?<2V@&'(8@^,Q_0\+ V%IH1:CR@7CV"2QTQ?'-Y$ N,BL3U@&"K.,!,! M=9(^_NNW'I$H'L$D \7ZVO!V$A@_B4T"PU!MAIEH!+,>P<3 .%, 3Y%5?9#K M*\1[2V#,I8\5\LD?2.4X9-FAE/# %40GR@$$DFR"%&,W0083TG!$+F80X ?X M6;-OWJ0TK^>^I>7KX5A-7HJZ+O+VUQLL$ !V& & M 'AL+W=OK2]U\;0_> M=XMO57EJ'Y:'KCO?1U&[._BJ:#_59W_J?WFNFZKH^LOF)6K/C2_V8U!51AS' M:505Q]-RO1KO?6[6J_JU*X\G_[E9M*]5533_;GQ97QZ6M'R_\>7X_!^^^_/\N>FOHEN6_;'RI_98GQ:-?WY8/M+]UIHA8%3\=?27=O9],93R M5-=?AXM?]P_+>'#D2[_KAA1%__'FM[XLATR]CW^FI,M;FT/@_/M[]I_'XOMB MGHK6;^OR[^.^.SPLL^5B[Y^+U[+[4E]^\5-!R7(Q5?^;?_-E+Q^<]&WLZK(= M_RYVKVU75U.6WDI5?+M^'D_CYV7*_QZ& W@*X%M W_:/ LP48+X'V+'XJ[.Q MU)^*KEBOFOJR:*ZC=2Z&AX+N3=^9N^'FV'?C;WVU;7_W;9UEJ^AMR#-)-E<) MSR1T4T1]\EL+C%K8L KGCPULM2+)<0L&UF#&>#.O(1!O8;P=X^T\WHH^N$J2 M47(:)7=$J8U%)4@6YUF*W2303:+-9]']PXZ,:I4KI&( N89Q!UI MD,GY"-*84-=BT)$#':.<.#W65F+W?T0?S6!JDL8FQ2S-("(J;()4P9[!T"1- M38HEQ$D3D1+'"@\ G%F(58RYR9J)%$N,,X*B$:HM4"6AWF%,3M;DI%ABG#45 MC96>MT"5S ?THQT,3]9@[%<&THXFH^X:K:'04\R8GJSIV2-/>M%N:Q(8]$:R4X@XBQD!J.3-?-8>0%K0#720!.: M YB=#-@I0;1A@$7]U %1^+'#\&0 3Y(D9P1/DR@_0)9R8)W'F)\,^$D2YD"D M%C2LX7D77.@9#$^CX9E)EAM-1:=V.D!$_4(Y8 :STP!VDG*CJ6A)OG-!IA#' M#0:G > D^58Q8$EIU7X4J4P2V+Z;P.X:L)/D:\5H*G(NGQH@N@MYP> T>JO> M;\.E%ZN:R23T@&;^2^9-HOEI'V5.SDR02KT/HMEI;>6;E_%@NUWL MZM=3-QR,SN[>#L\?>3CM%?8ORI+^'@B_WMHO3/W?#5]=^;ZTGX]:*KS],I?W3[5\/Z/U!+ P04 M" !J.09/#^X+D[0! #2 P & 'AL+W=O-\=&'-% UJX*]-!BS>5L5IX-&W-7&=! ME!&D%>.;S0W30K8T3Z/O9//4]%[)%DZ6N%YK87\=09DAHUOZZ7B6=>.#@^5I M)VIX ?^].UFTV,Q22@VMDZ8E%JJ,WFT/QR3$QX ?$@:W.)-0R=F8UV!\*3.Z M"8) 0>$#@\#M O>@5"!"&6\3)YU3!N#R_,G^&&O'6L["P;U1/V7IFXSN*2FA M$KWRSV9X@JF>:TJFXK_"!12&!R68HS#*Q944O?-&3RPH18OW<9=MW(?Q)KF> M8.L /@'X#-C'/&Q,%)4_""_RU)J!V+'WG0A/O#UP[$T1G+$5\0[%._1>\BV_ M2=DE$$TQQS&&+V/F"(;L$NPG=_*+Q=)TA6"9)(D/RW MQ+68_5])V**G&FP=I\F1PO1MG.2%=Q[8.Q[?Y'?X..W?A*UEZ\C9>'S9V/_* M& \H97.%(]3@!YL-!94/QUL\VW',1L.;;OI!;/[&^0=02P,$% @ :CD& M3XUM#L"T 0 T@, !@ !X;"]W;W)K M)+=,"]G3,H^^LRUS,WHE>SA;XD:MA?US F6F@A[HB^-1MIT/#E;F@VCA._@? MP]FBQ5:56FKHG30]L= 4]/YP/&4!'P$_)4QN-.D:,A"WYQ?U3[%VK.4B'#P8]4O6OBOH'24U-&)4_M%, MGV&IYQTE2_%?X0H*X2$3C%$9Y>)*JM%YHQ<53$6+YWF7?=RG^2:[76C[!+X0 M^$JXBW'8'"AF_E%X4>;63,3.O1]$>.+#D6-OJN",K8AWF+Q#[[4\\ \YNP:A M!7.:,7R+61$,U=<0?"_$B;^B\WUZNIMA&NGI-GJ:[ MDNP)9%,C>+'$'D_Y? M)-OT5(-MXS0Y4IFQCY.\\:X#>\_CF_R#S]/^3=A6]HY7C?UOC/& J20W M.$(=?K#54-#X<'R/9SN/V6QX,RP_B*W?N/P+4$L#!!0 ( &HY!D\'2''> MM $ -(# 8 >&PO=V]R:W-H965T&UL?5/;;MP@$/T5 MQ >$7>Q_KA>)1-ZX.#%5DO&G@"_Z,_6;38 MPE))#9V3IB,6ZIS>[P_'-,3'@)\21K9>7;G-Y14D$M!N4?S?@%YGJN M*9F+_P874!@>E&".TB@75U(.SAL]LZ 4+=ZF779Q'Z>;Z]L9M@W@,X O@+N8 MATV)HO)/PHLBLV8D=NI]+\(3[P\<>U,&9VQ%O$/Q#KV78I_PC%T"T1QSG&+X M.F:)8,B^I.!;*8[\'SC?AB>;"I,(3_Y0F&P3I)L$:21(_UOB5DSZ5Q*VZJD& MV\1I>5=!O:>QS?Y'3Y-^W=A&]DY7S;VOS;& TK97>$(M?C! M%D-![C)-+.5E4KM=)HJ[;/3.(D: &G0";;OR^0;)JV45\ &Y_C8V.R >V+:P$\ M>=7*N)RVWGR4-7"QQO=;"_CR#PB&G6_KF>)9-ZZ.#%5DG&O@"_FMWL<%B,TLE-1@G MT1 +=4X?MZ?S/L:G@&\2!K,P.7YC?U]JCW4$NP7=_*#RN$^Q7"?:)8/_?$M=B[O]*PA8]U6";-$V. ME-B;-,D+[SRPCSR]R>_P<=H_"]M(X\@5?7C9U/\:T4.0LKD+(]2&#S8;"FH? MC_?A;,&UL?5-MCY0P$/XK37_ E64Y73= M^=%A91B5_:SG2>9YZ93O/1V!?7 7CRJJ1V M!>V\[X^,N:H#Q=V=Z4'C36.LXAY-VS+76^!U!"G)TB1YPQ07FI9Y])UMF9O! M2Z'A;(D;E.+VYPFD&0NZHS?'DV@['QRLS'O>PE?PW_JS18LM++50H)TPFEAH M"OJP.YZR$!\#G@6,;G4FH9*+,2_!^%07- F"0$+E P/'[0J/(&4@0AD_9DZZ MI S ]?G&_B'6CK5NXIF8O_#%>0&!Z4 M8([*2!=74@W.&S6SH!3%7Z==Z+B/T\W]#;8-2&= N@ .$<"F1%'Y>^YYF5LS M$COUON?AB7?'%'M3!6=L1;Q#\0Z]UW*W/^3L&HCFF-,4DZYCE@B&[$N*="O% M*?T'GF[#]YL*]Q&^_T/ANVV";),@BP39?TOM+]IT"CNO&E:9GL#O(X@)5FZVUTSQ86F91Y])U/F.#@I-)P, ML8-2W+P>0>)8T(2^.1Y%V[G@8&7>\Q:^@OO6GXRWV,)2"P7:"M3$0%/0V^1P MS$)\#/@N8+2K,PF5G!&?@O&Y+N@N" ()E0L,W&\7N ,I Y&7\3QSTB5E *[/ M;^SWL79?RYE;N$/Y0]2N*^@-)34T?)#N$<=/,-?SCI*Y^"]P >G#@Q*?HT)I MXTJJP3I4,XN7HOC+M L=]W&ZN?XPP[8!Z0Q(%\!-S,.F1%'Y1^YXF1LRN[*CU#G/]AB2&A<.+[W9S.-V60X M[.&PO=V]R M:W-H965T)W^?0$[KIOZ!9CAG#,7AFQ$\VI; $?>E-0VIZUS_9$Q6[:@ MA+W!'K2_J=$HX;QI&F9[ Z**)"49W^UNF1*=ID46?6=39#@XV6DX&V('I83Y M?0*)8T[W]-WQTC6M"PY69+UHX!NX[_W9>(LM*E6G0-L.-3%0Y_1A?SRE 1\! M/SH8[>I,0B47Q-=@?*YRN@L)@832!07AMRL\@I1!R*?Q:]:D2\A 7)_?U9]C M[;Z6B[#PB/)G5[DVI_>45%"+0;H7'#_!7,^!DKGX+W %Z>$A$Q^C1&GC2LK! M.E2SBD]%B;=I[W3L.C-FR!<7M M#7:@_4V-1G'G3=,PVQG@520IR9+-YA-37&A:9-%W,D6&O9-"P\D0VRO%S?L1 M) XYW=*KXT4TK0L.5F0=;^ [N!_=R7B+S2J54*"M0$T,U#F]WQZ.:^E>'3'R,$J6-*RE[ZU!- M*CX5Q=_&7>BX#^/-[96V3D@F0C(3]I' QD Q\R_<\2(S.! S]K[CX8FWA\3W MI@S.V(IXYY.WWGLIMNE=QBY!:,(<1TRRQ,P(YM7G$,E:B&/R'SU9I^]6,]Q% M^FX9??=Y72!=%4BC0/I/B?L/):YA/@9ABYXJ,$V<)DM*['6[:4G1#O=O%UO_0#FQ%PR+658&8XPP8XMTHFC]^]J#]X6N+U_*+^ MV15OBMDQ!1O!?Y5[72S]F>_MXOE):5'U*B:5BGUT8UF[L>WU+S2<$/:$<""$D_\2HIX0#03J"*3+S)7ZB6F6 MI5*TGNR^5L/L3T$7D=G,W ;=WKEWIEIEHN>,QD%*SE:HQZP[3'B-&1#$J \6 M(6:Q#N_HX:W!YAY!XP<6$5I%Y 2B&X$0%YB@ A,G,+D1B$998I@);A*C)C$B M$(_VNL/$#E-WFQ4$N$F"FB2(23(R2>Y,Z".3*6HR14RFN, ,%9@]_\'FJ, < MR6 V*A/#S'$3&N"G([B72![L%'UPP.CSI5+T *UH^$2Q&"@9'R)RU18JD$?7 M0967BU/MVO=5=.C2*]>DR3]XU^*_,WDL:^7MA#;-R;60@Q :3"[!B_FU"G.K M# L.!VVG4S.776OM%EHT_;5!AKLK^PM02P,$% @ :CD&3Q^ZR2?R 0 M7@4 !D !X;"]W;W)K&ULC53;CILP%/P5Q >L M@PU)% '2)M&JE5HIVJKMLP.'@-9@:CMA^_>U#:&L8U5]P1=FYLPK=:HI4T7 MYJG=.XD\Y5?%F@Y.(I#7MJ7B]QX8'[(P"N\;K\VE5F8#Y6E/+_ -U/?^)/0* MS2IETT(G&]X% JHL?(YVQ\3@+>!' X-I>#NI:"LM?1_'IK/C,.G?:7X"G@AX)D3Q M/PED(I#_)<03(78(:(QB>W.DBN:IX$,@QJ_;4W.(HEVLNU^83=ML^TZW1^K= M6QZM<8IN1FC"[$<,7F ,*B4F6[T7(R__+A0O)]N,S1?J?D?4$L#!!0 ( M &HY!D^GLB-"\P$ %P% 9 >&PO=V]R:W-H965T0'J/DFC0"I331MTB9%G=;]=L(EH!K,;"=T;S_;$$; F_H' MVY=SSCW'&*<]XV^B I#.>T-;D:%*RFZ+L3A5T!#QP#IHU9N2\89(M>1G+#H. MI#"DAF+?=6/6IJ!YZG[")IW<*!.^+2-(3_?@;*^@QYZ%9XJ<^5U 6< MIQTYPW>0/[H#5RL\J11U ZVH6>MP*#/TY&WWD<8;P&L-O9C-'9WDR-B;7GPI M,N1J0T#A)+4"4<,5=D"I%E(V?HV::&JIB?/Y3?V3R:ZR'(F ':,_ZT)6&=H@ MIX"27*A\8?UG&/-$R!G#?X4K4 773E2/$Z/"/)W314C6C"K*2D/>A[%NS=B/ M^C>:G>"/!'\B>.%_"<%("#Y*"$="N"#@(8K9FSV1)$\YZQT^?-V.Z$/D;4.U M^R==-)MMWJGM$:IZS;TX3O%5"XV8YP'CSS#^/6*W1GB1=X_96U3^0K R.3GU MK4Y]PP_F/8+ +A!8!0(C$-Y%3191!TQD,*W!Q,DR[!J3>,$B[+I7X-N]AE:O MH<7K9N$U7/GPW,?%M]L-H'@.\N)HX7;=[5]N(ZO;R.+V<6$D6KO=))M%%SP[ MMOK>^4;XN6Z%&ULE5?M;ILP%'T5Q ,4;# ?41*I23IMTB95G;;]IHF3 MH )FX"3=V\]\E!)S7*5_ CCGGG.O?0_8\XNH7NHCY])ZS;.B7MA'*G+BN>[-J@/'.HZP9.GJ2%O9RW8X_5?SM2>U!LPDKZOJA3)JV(S.F MEFO;#+:KT_ZGYK-6H^LRJP] K#+G&K %F0#@J@R$-BM)842!! M-8DI1D-LI@@67T,>D)"',_7@A'DM@7=%X&,"'Q+X+8%_1<"T4CL,:S%%AV%1 MJ-6RF:)HY(K!% E "J&-$-($-X^YQ$DB$ &D=;E M"*/-^!I@(L-4Q#"1&!!H5EHAC.X%A#&T,7&Q\5U 89A48GAWD-O7A4#?WQ,* MLM#<\-"#QBVH.M#4@P3[EGA *="5$,C0J@3;FP!_1Y'^MNQ P:BB.&#,,VIA M^Q+@WTCO63(U,/7,LXOZYH[DV(G4N#$6#/\J@=]0@Q[EA(@YNEB'2@VOU'4AW2HK:> MA52[_W:/OA="C7 /!CC5O$7VB/._GE M3%F+A!RR"^ ]P^BD@UH"HB!(08N:SJ\*/;=G54&O@C0=WC./7]L6L;^OF-"A M]$/_/O'67&JA)D!5].B"?V#QL]\S.0*3RJEI<<<;VGD,GTO_4[C>Y8K7P*\& M#_RA[RDG!TK?U>#KJ?0#E1 F^"B4 I+-#6\P(4I(IO'':/K3DBKPL7]7_ZR] M2R\'Q/&&DM_-2=2EO_*]$SZC*Q%O=/B"C9_$]XSY;_B&B<15)G*-(R5<_WO' M*Q>T-2HRE19]C&W3Z78P^O3R]E;)6NL #":0N 5BIT"L!>!,(+5V9&12 MS70CDP3CS]J7Q>1V,;E;0LZ,0J=1Z#":64;ATU(AS,)5G$%H&5U,;AUD"/,X M#FURMX2<&4V<1A.'T95E=&22AZ6@W,XTLTY^^\S%89!G,'4GE#H32AT)Y6Z! MS"F0+2_RE5-@]9Q!:)?NR.2.,K..:0$X2REWII0[4K)OF?QII7N162DY0%,Y M5DK@X:)43^-WQ"Y-Q[T#%?+.U3?CF5*!I6CP(H^]EJ_Q-"#X+%0WDWTVODGC M0-#>/+=@>O.K?U!+ P04 " !J.09/+I&E4S 6 !<3@ % 'AL+W-H M87)E9%-T&UL[5Q;D]LVLGY>_@J4CW..7:61A]+<;">NHF?[@; BT!*RFS>SC[$D42@T>C+UQ> \WV6 MY>S;)HJS'UZL\WS[[LV;S%^+#<_ZR5;$\&29I!N>P]=T]2;;IH('V5J(?!.] M&9R>7KS9\#!^P8HX_*,0UTD1YS^\&-B#%Q^^S\(/W^FI??;VZNQTV,GT_&EK+'YQ\E/G^'N1A@GN,V W/#>F:DE9?_M;FZP< MH!$0G=N(KW:?+GF4&12OBS2E"6'FPUY_%3SM7/WDQ!Z<#.U.YA4-M8=;^#G; M'?OSX-!LXJ!U;MN.KZ>3F]'$&]TP^.1-Q^Z-,XLQ/VX-VP5R]?LYN5P=##; ;K,,JS-;F,CQ_$'T7XR"/8O+&&MT[2 M_"07Z88M>/P["\0VR4)SW'TJMCP,F/@&7IT)X_DT7XN4I<(7L-(B,@?,DQR$ M[BLKX%DFS$4FT\G)_GV-DW@EN=T>8.@^!?Q)P;M0"BB +2J_QV*1[PZ=A:MU M?I(L3XI,M'.&"/?&"[A-PXY_$JA.TK,JW+24G$27RR M7QIR7/LS+:6QZWQTQV!B(],$%'& KR(-\U!D+%FRJ!1@E/#8H.OX/F)PQK;\ MB=,^0'K<]],"?/J=P6'* \-YR1(,O0D.LHU"O@@CXF6_>>P96+>1/;O_A:<( MRL;T<7/_I""4BV](Z[#:]G!Y/;V[<^<2$)P)@<; (0L0S_L,'OTQ-P(<,;&2Z\UQ_XI) 8]W,]&GV&\^V7$QE//>Q82 M#X].*PRO.F?TT0OOJ' N6-YI!/,+1SLV=.W&]^*5T:.U!2O9W.C("=906/ M?8$1@*0%^1)MMS5PCS;;*'D2@F5YXO_.DBW6!1ED("+UP\S$A8[Q4%(L18C; M)I#[M@U3\SNQU/?ZF[Q'.LOR3DP90*H9QK +O6H.L$_RBR')/##(P<0@YH@^4) M?%Y&PL\I0: LND!=P-*85X(NXA4D1GGX*./5JPSTS+>@IR#\QA8B2KZ^-H#L M&$I[]^-.OHR\ _MQXT>A]P-K9%6"WY7;WS4RQ",F0$SSA0C U-)D X+B4?A/ MLLYFAAF6G!@$BM1?8T8(X[>MB?J^&>%NFMTI:*#]&$+$9HLG]DI)_;7BZT^( M7<6H_6)74)(96$(;^ZKRT3+A##7T^$EF5B10VSQ)%9)$6S+UG2&'\NM6D2PA M3L3^?D% U)Z-'&\DHYXGTQ/Z@"'J"^0@DY;RLVL@1N'1)W(8$L>I@QF%T9:K^<^PW558=6T7]-J8B #%)0DU58![(S]'@$W M)3$8WNH+LGP(#=UUJLZP%^(OV\%DQ!8BI_WJB4'8WK0IWD_) 5\!#_0)0<9H M41"MY%"CI"0&%/B^,K\#! M@*.#L*SK,G<"V>D=U1.&/829#WE=D5+L6XE8I#M;^,WIJBDGT_F(V>R__^MJ M8-OO62.I\-^C16< M 9C LF*1A4'(4\JV_"1"@P23B9YZE.TJ9C$?YO&39I5A'!;QBJ\DGS@R$# K MV6K]H3_RK2CRT,]Z%O"P@36B)S*D*(Q#GT2&X9 MBBA 0@EL-$I63WWFQNQ6+,!)H0B#_5SV:OL!TT%!X):2G4)-$9P+<,3'\)%Y M5#:4@4+K8P[1N-H?B ;@1?>;1 M#S\6$3)HVS4&E18SYFR@?O!Y#.D_P3(RZDE&-2?.C9>5G" ##& I82U<3!SO MQOF9Z6+RCJ>_BYP$!1_]-=5M4H]*@8 G"GZ<%<2HS::(1=,LJ]\KN^2 N0"K M.5C%R1K5XBMJ#2,$6\.5'F(JPGX"] J2S0'ETDK)2:5C)\JA!%FM&TQ#AJH\ M%"EGX2H.ERA#!+A'$1="I$ M20QM@<"X"6J3O&/82&**$SYDU !!$+&^0FTHG0@VDM4U8X\8U?5KODZ%L/"7#$JJC6S Y;@=@5TX4!B@#]9:)Z?EM*0#TW#O^P&T5=G_O9Z-Z9'8']"YZ%F2R9 M(+%(CP+_00G^;>N1+FN028[_'-VV*-/4)?YBM>J2O:I!^+Z%FFA#0".%(>$= M\Z4TH+24/((RQY@$A=F-S*;0S3RH( ,TE$G29\.SGE[;56M7ZH,Z"Y/X>*66 M+O''=3R8J1GJHR@I:>MF'BQV'0+884PJ8EX$B#\]%B28IUH 45$1((1&D"-K MO4/Y :E1EB'ZHC"YS.I+HDTO):"&S?:P75=$TNFJ*-NK"@M*@RG&)91)8'+; M(K(6.92RJ^* >SOS&H)XC@U94 D4 +8+@4 6*-[^4<0$AI*YO,5< 0HA&]YG MEI!14UNQ[&$U3/,)SX%KIJC\&(2,UD1KX:Y!1:+4X)'6!V*1XFC5AN; *IVC M#G22F1V/2F5)HTU"IBD!1!A"(H55>C$*]QO^A!+%$L1'#>A=@W@ 'T%J=!9. M,H G9&& S;)(T=J2C40#P#SWT\2]=:\=/*V]OIX^T!$7NY^.W>N6!DD3R^JQ MD5=^N053\3'#.P!KPQ+6#G!!XF];0'I"Y&,'&NUK(R">@TU#/(G"*EFL0ZV4 M;YN36W6;2\G\,\SSXES;;9*)PZ3_:EON8>DMMGGYG >R"8V4T#H)_NR+$O[H MF%:#;!]K@V9%Z">@M7_*H&G0LB_JX81R(1H#P_7S5.1IDFUUYBZ3H1]Y3)FR MK:Q\4>0T&2T=ZSI"#O+$E.R\LNFZE832A&M8<44Z$,#,IH&I"5&!*@"3R&29%% M3Q)-_ @*2. 182C32JEJ[*BN'JO:&22]8"Y0WY*)8&#";+JAT[X.7S),U9FD M-&H#HPK$,2P1I'%F:+[4/JJ0!6]KE9PPW8'L4E@\2\''XBM+"]0O6(W%HZ_\*9,6HS %;%7VE10'K,9!JW[Y!M6%_478 M4UVH58NHIP18Y=9J$I!'R]?MK225+:G2 \K&M+1]M(9$1B/YO*8EY7(+'E'8 MI)N!+4A'GB[%O6-47P7N&/?U"%Y"C:]N*U/XV[K=4!;@NV"$'0S[O&]_U[>J M1Y8.R\C76_D/XH'*OKJZ0BC%IZUX9^F[29;=.S\?P+]G5^?670+%"GL4 ZP M1VLXN+ &0]N2C3F3',RZNKR"?R_MB]W%S9TU'6OBYDS+4N[:$UJ5][ M,4;8/?OB7#$$%>0]QFWLFU#:$80R?"GA=T0.5YHRI5KZ-QVUEF&:R<9%$WHQ M2% CD@8E421UO6U;O@H(BR>KCO+O+$+&B_?6@SQ=XM@M646BQ#1I/& TG&&D M@87"I)1RME-Z/\'L31A!&/;7'!F!F)1A:^E]NZ*2SU38HH-;: M]))\Q!X4+;Y!ZD; )BF1_C6EOIGE8--+1#+! MQJR%.N92HZ4F>;5D" $S26S?N=4(.6X,B,PARUDJ$D@2RP7=B\VQ M 0W^*271F87B1:DT8S<)P>X/Y"#2P::.VXI87VZU/(=ZA=UK !Q4)V87$777 M9!X89N4!Q.O24PX5@AN5;(&47IX".P Y$9D'7?REL$RUW$8>'ZG>0AEO34>T M=N"C$3V.Y HE"-S8)3?&&8KG/3CR,%?=J&+7SKT[5Q?3?G%F,Z?E-+=9.8;' M';0?JB#/R@KR2*ZH&@((7(N3#;6OJT[T_*[L2V4NK,['AF//E\K@E M41$0$E-J*"5X:BN[L0+,-U^GU/V6*V+ I7/&DBVZ:XWG ]@KH6>PJ15PNY+@ M!L1DK [E[:MB2[8\/ 4'5.:CUTB*O':?B05%*M%&LP]284ONRP-:B0!4>0E8 MQ,^;<$WM;\A/I4HXG46!0:G@->R??J<#TPK2\K>:)V0:S\OC#?A_).1YH>2H@PZN/+CJG9Z> MXG^$#F"[)#?L-=!Q(%L\-PJ5A J"=GZ/MX6A]_EZU!=42TLK* M]>C445X+).G62LN>NO$'6>VCT&%$FTP9^?7E"EQ/'JS%Y3W#!F^7)6_$@E5N M(.5X)1%V)@T$1T,=7U JML*.&"$-RK&?(T7+-> M+\DDYE;W=73.$NC,L\P=D<9.L @PA< $ XIY>(12\74SAI* O$X9O@D.R-DL MN7$A*:#:4%_=BJ$0"X%V)<6,@BFS!:OEUDW51ZO.*,R+P<9RRGQJ&J)91;.I M]#'B_N^TG.>O$VIYR6(2O0(';9) 1+O$K5WBQ19-4IL52K5<2UZZ51J@9JHV M@]+Q,,6]\3!QA^KN]Y,E]N^KNRS*B0?]MY#-O]RXMC&3[O#Q3#?GGAJ,9Z-Z+5HY[5GM#:_6%G"DGY MV>?I^&8T\_Z'M;\/T\P7R:_;LL7N5S$H03ROCAAJ:ZKR0=_/=_8TY7?B>G-Q M9=P):6ZY>Q6$2F[9T69/JKD!SF-7HD=6;4E>R*>44.=3MA#&-Y:W!^:F. M@HW/KD1%9!^+B!-(RYH3;?NL]W8X[-EG9Y9]=MFSKX:]2_@, 1WO9^/$B>L] MFS&\08<$7@-7-0:/YJ^:;]N]L[?#WM!&/GN7]E5O>'EVW'S8R&L+MGCZ%K9V M89W1ZA>7%\85SB_X>H[W\-$#:\"/\RF;?QXQ?27>^SP:S1G><]]OH0BHLM6* M^(471=#9*?3N'FX<,MJ+TFB/9\Z:QO(FD'W>:TG&PHVZ.$?91.7MU+U!0&BD M7>"_ABT3&"1@ S#"2H4Z6J#T#7YL#MXZ?_9\DKV:T_U+ MXYH^Q!5(>&26O]-8+=\4Q;Z3TWKW_#]=XB.ZQ,>@^E'ZD>\PJ6MEQIL=_P'G M_[_@?-#[)YA687G^FKVZ$3D4PMGQ;QF!8_39Z:#C+TDTT#T@VI2N5VU.OL"N MANXM]M@VXNIO7)1OP+#?(KS91S?.#;#_Y4\<>QWS>@@><9U^U_[6MDKKS1<# MG]=IW#VHV,=6^1+_;YOV%P-+.3A*#K.R RR9GXO4>.?9MF7=;;P'U<#6SC7E M;%8>FM@#R'*?S'OOAPSPS\69YUBI%M_^C;:_"F#&DK]R@U(YXUKLF96QYSD[ M[8Q+1I:T+T2U2\+@]9EM[8YMO='7OQ'ACCZL5F:;8 M#^UZ3[8)6WATHFY))7$0RK,Q74.I%U/503_CM>.>?:C5?&]0;YM0O_V-G)VJ MLE9'&K$>$L2NMX=G[27O[C"JUPUA8TUL+-99&^^.Q,+>)(K5L_EKU;SO?&6Z MHX%NR%FD/H:"E5"ME[+''>^>&^Q.'?9/3<[4F^*Z@UI.[G7\Q0FGO:W<:)2; M+W@V&[!=,JCRK;WV4PU3[9.2?<,GFBU?U4TU7]?;AJG!]&W9PS7'JV8M7=?> M0WA2[\":?G&X!7NL(-F_F'YWKTNV[MYW^MJ3],YLO [C4)0.+P;O&[!V".8: M;Y,KN&PWM\9(=^S1X1>NUS&^\3[[7LJ-D4=0KJRN_",,7KN'=*78_^IPJ8.Y M\;\Q\:6Q#;<;3/=PKF3S# Z,F6^R+/_P?U!+ P04 " !J.09/$A#\OU$" M #6"@ #0 'AL+W-T>6QE/O_42GWQ#/GQX,7!07A[=+&- M'[K $4:>XVV>X&AZBH/?)ST.[^)O7[[>LQ5CY*>; M<6Z)@V[7T[B08MS\$^P!4YEP0 O"$GQ)&)TK:K,*PBE;>7AB@4PRJ9 VIVZ4 M119I[GPX\IZ]$!T/IT(J5]M7\+_S;OI6H/>L0,K8('""/9#&-=$:E+@RCIOL MP!]"J+-GJ]HH+!5919,S/":XP1292Y6#&LI$N(?2F$%AY2A:5G;4L@YL4&O) MC9%34DI!G(8^HS,,;0:,W=BOY6.QP;TLD)]CCR3$R*KH3;/JSAQ/+722U]D\ M]SIMN!,OJNE"ZC>M68YPOKTX<*V@H$OG+XM!@&$G=_F <+1CL6 M3&/2UT&55/3.\-FKDAD %$8+4)IFZ\AG1>H9+'5_G9;%KIHG>ZCYL?>Y! &* ML'71YNX_Y5W^SXIM7_EKS>YO95OQ(XH\.7_Z&FT7W0.1TWT0^:^/.^C:SEIO MV^AL XKF+66:BDYN1?,[7=6>#0=9LT&B@2/]GO(:"FL^NX9_19O8YW(2 FX8F69#,-!@$@ M!RUFK-%4ID33N12'/>,/TR *P)9)I7&W=I_9,LY:]D+K/E([\;P0DKT(KDF# M*RF:IG^K&^A?,BNH/SWW5&I6O4G49%,0PSH-)@,SX1-3;,,:IG]-@[[=T,#L M(K2VT>MP>AY%O)+_(J/8;EE%4U$=6LKU44=)FVYUKG9LKP+ 24NGP2D%$%X# MR+6A 8@?IS*YW5[,TJ@^[DL;Q5YA@;QB9D"B.NK _4$F>9;"#,,4F!;.ERB- M2Q.@K(0%N@,6Y- !.?Q R!]#"_+, 7GVOR!/XN'28-[!K,0@GUF0(P?DZ".5 M/+,@QP[(L5_(.N6CWPRP;O33$! M>'V+#5?7+'-0+B"XC9>=KC:FTU(\>XKSQ_BF7$G<6-.;8Q7383>?899Z%\^P&Y M/"?R;3KO?D#8S%P?&FK7\\CE.E%O.^'I0E[3+>.TSLP2RO2;>WZUDJ!['"O& M:!P9>]@>FB8Q?3E?"M)?H;LY3O]-;GX#4$L#!!0 ( &HY!D]_ 2!Y*@$ M #L, : >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'.]UTMN@S 0@.&K M(!\@PY"$)%7(*IMLVU[ @N&A $:VJR:WK\NFCI387:#9@)#1S+?Z!<=WZJ7M MU&C:;C+);>A'4XC6VND-P)0M#=*LU$2C.ZF5'J1UC[J!2997V1!D:9J#]F>( MT]&?F5RJ0NA+A2+YE+HA6PBX]?"M]-6T1-; ?,.56^!>N4_TG_6JKKN2SJK\ M&FBT3Q1_"P0\!V5A4,8.6H=!:W;0)@S:L(.V8="6'92'03D[:!<&[=A!^S!H MSPXZA$$'=A"FD3*F_*18K/EKC9%<(W^O,1)LY"\V1I*-_,W&2+21O]H8R3;R M=QLCX4;^>UJ>,4]]N=^K MM'5;".;KXFV>I_XBX.%?X?0#4$L#!!0 ( &HY!D^5@!M(80$ &@- 3 M 6T-O;G1E;G1?5'EP97-=+GAM;,V7VTX",1"&7X7LK6%+4?$0X$:]51)] M@=K.L@T]I2T(;^_L B:2-<$ R=QLMYWI/U^[DS_9\<TW:] MD9X4(@2CI]K2!&K>!?:+ZJM 3EY=+BEC*%"$*E&B!;4Z9:1%#O.6HWW_'.1,ROPJ(P M6QOV*Z&\'$?>&.@&:"/GK)RQ+:"K5!O8/OE)!??=('V$?H@8C5EW' ^19AA- MK$D\YQ&A:1T%ZJCB*'VY#_OEXZ)][[KPGV!B[7#:K9^/8TB$XYH(QPT1CELB M'",B''=$..Z)<#P0X> #*B!4')53L51.Q5,Y%5/E5%R54[%53L57^06-M1U+ M*[3[B^33^\6^/FM_L*;?4$L! A0#% @ :CD&3Q\CSP/ $P( L M ( ! %]R96QS+RYR96QS4$L! A0#% @ :CD&3R?H MAPZ" L0 ! ( !Z0 &1O8U!R;W!S+V%P<"YX;6Q0 M2P$"% ,4 " !J.09/*W-)_.\ K @ $0 @ &9 0 M9&]C4')O<',O8V]R92YX;6Q02P$"% ,4 " !J.09/F5R<(Q & "<)P M$P @ &W @ >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0 M ( &HY!D_44OV-$@( ((& 8 " ?@( !X;"]W;W)K M&PO=V]R:W-H965T&UL4$L! M A0#% @ :CD&3^K^0V%2 P / T !@ ( !JP\ 'AL M+W=OQLL$ !V& & @ %Q M%P >&PO=V]R:W-H965T&UL4$L! A0#% @ :CD&3P_N M"Y.T 0 T@, !@ ( ! !X;"]W;W)K&PO=V]R:W-H965T M&UL4$L! A0#% @ :CD&3T]R8Q>T 0 T@, !@ M ( !,"( 'AL+W=O&UL4$L! A0#% @ :CD&3Q*Y]>NT 0 T@, M !D ( !!28 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ :CD&3]T2Z9TE @ QP8 !D M ( !R2L 'AL+W=O!0 &0 @ $E+@ >&PO=V]R:W-H965T M&UL4$L! A0# M% @ :CD&3WE#( 'AL+W=O M&PO=V]R:W-H965T&UL4$L! A0#% M @ :CD&3[3=XUJ< @ 'PT \ ( !55$ 'AL+W=O7!E&UL4$L%!@ ; !L +P< !)7 $! end XML 31 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 32 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 33 FilingSummary.xml IDEA: XBRL DOCUMENT 3.19.2 html 51 187 1 false 12 0 false 5 false false R1.htm 00000001 - Document - Document and Entity Information Sheet http://biolinerx.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00000002 - Statement - CONDENSED CONSOLIDATED INTERIM STATEMENTS OF FINANCIAL POSITION (UNAUDITED) Sheet http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition CONDENSED CONSOLIDATED INTERIM STATEMENTS OF FINANCIAL POSITION (UNAUDITED) Statements 2 false false R3.htm 00000003 - Statement - CONDENSED CONSOLIDATED INTERIM STATEMENTS OF COMPREHENSIVE LOSS (UNAUDITED) Sheet http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfComprehensiveLoss CONDENSED CONSOLIDATED INTERIM STATEMENTS OF COMPREHENSIVE LOSS (UNAUDITED) Statements 3 false false R4.htm 00000004 - Statement - CONDENSED INTERIM STATEMENTS OF CHANGES IN EQUITY (UNAUDITED) Sheet http://biolinerx.com/role/CondensedInterimStatementsOfChangesInEquity CONDENSED INTERIM STATEMENTS OF CHANGES IN EQUITY (UNAUDITED) Statements 4 false false R5.htm 00000005 - Statement - CONDENSED CONSOLIDATED INTERIM CASH FLOW STATEMENTS (UNAUDITED) Sheet http://biolinerx.com/role/CondensedConsolidatedInterimCashFlowStatements CONDENSED CONSOLIDATED INTERIM CASH FLOW STATEMENTS (UNAUDITED) Statements 5 false false R6.htm 00000006 - Disclosure - GENERAL INFORMATION Sheet http://biolinerx.com/role/GeneralInformation GENERAL INFORMATION Notes 6 false false R7.htm 00000007 - Disclosure - BASIS OF PREPARATION Sheet http://biolinerx.com/role/BasisOfPreparation BASIS OF PREPARATION Notes 7 false false R8.htm 00000008 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES Sheet http://biolinerx.com/role/SignificantAccountingPolicies SIGNIFICANT ACCOUNTING POLICIES Notes 8 false false R9.htm 00000009 - Disclosure - ISSUANCES OF SHARE CAPITAL AND WARRANTS Sheet http://biolinerx.com/role/IssuancesOfShareCapitalAndWarrants ISSUANCES OF SHARE CAPITAL AND WARRANTS Notes 9 false false R10.htm 00000010 - Disclosure - SHAREHOLDERS' EQUITY Sheet http://biolinerx.com/role/ShareholdersEquity SHAREHOLDERS' EQUITY Notes 10 false false R11.htm 00000011 - Disclosure - EVENT SUBSEQUENT TO THE BALANCE SHEET DATE Sheet http://biolinerx.com/role/EventSubsequentToBalanceSheetDate EVENT SUBSEQUENT TO THE BALANCE SHEET DATE Notes 11 false false R12.htm 00000012 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables) Sheet http://biolinerx.com/role/SignificantAccountingPoliciesTables SIGNIFICANT ACCOUNTING POLICIES (Tables) Tables http://biolinerx.com/role/SignificantAccountingPolicies 12 false false R13.htm 00000013 - Disclosure - SHAREHOLDERS' EQUITY (Tables) Sheet http://biolinerx.com/role/ShareholdersEquityTables SHAREHOLDERS' EQUITY (Tables) Tables http://biolinerx.com/role/ShareholdersEquity 13 false false R14.htm 00000014 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details) Sheet http://biolinerx.com/role/SignificantAccountingPoliciesNarrativeDetails SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details) Details http://biolinerx.com/role/SignificantAccountingPoliciesTables 14 false false R15.htm 00000015 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Schedule of Composition of Right-of-Use Assets) (Details) Sheet http://biolinerx.com/role/SignificantAccountingPoliciesScheduleOfCompositionOfRight-of-useAssetsDetails SIGNIFICANT ACCOUNTING POLICIES (Schedule of Composition of Right-of-Use Assets) (Details) Details http://biolinerx.com/role/SignificantAccountingPoliciesTables 15 false false R16.htm 00000016 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Schedule of Composition of Lease Liabilities Recognized) (Details) Sheet http://biolinerx.com/role/SignificantAccountingPoliciesScheduleOfCompositionOfLeaseLiabilitiesRecognizedDetails SIGNIFICANT ACCOUNTING POLICIES (Schedule of Composition of Lease Liabilities Recognized) (Details) Details http://biolinerx.com/role/SignificantAccountingPoliciesTables 16 false false R17.htm 00000017 - Disclosure - ISSUANCES OF SHARE CAPITAL AND WARRANTS (Details) Sheet http://biolinerx.com/role/IssuancesOfShareCapitalAndWarrantsDetails ISSUANCES OF SHARE CAPITAL AND WARRANTS (Details) Details http://biolinerx.com/role/IssuancesOfShareCapitalAndWarrants 17 false false R18.htm 00000018 - Disclosure - SHAREHOLDERS' EQUITY (Schedule of Share Capital) (Details) Sheet http://biolinerx.com/role/ShareholdersEquityScheduleOfShareCapitalDetails SHAREHOLDERS' EQUITY (Schedule of Share Capital) (Details) Details http://biolinerx.com/role/ShareholdersEquityTables 18 false false All Reports Book All Reports blrx-20190630.xml blrx-20190630.xsd blrx-20190630_cal.xml blrx-20190630_def.xml blrx-20190630_lab.xml blrx-20190630_pre.xml http://fasb.org/srt/2018-01-31 http://xbrl.sec.gov/dei/2018-01-31 http://xbrl.ifrs.org/taxonomy/2018-03-16/ifrs-full http://xbrl.sec.gov/currency/2017-01-31 http://fasb.org/us-gaap/2018-01-31 true true ZIP 35 0001178913-19-002055-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001178913-19-002055-xbrl.zip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�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